

CURRICULUM VITAE

Name: Brian J. Miles, M.D., F.A.C.S.
Clinical Address: 6560 Fannin Street, Suite 2100
Houston, TX 77030
Telephone: 713-441-6455
Fax: 713-790-4456
E-mail: BJMiles@houstonmethodist.org

EDUCATION:

1963–1967 B.S.E., Michigan State University
1967–1968 M.S.E., University of Michigan
1970–1974 M.D., University of Michigan

POSTDOCTORAL TRAINING:

1974–1975 Internship in Surgery, Georgetown University, Washington, DC
1978–1982 Residency in Urology, Walter Reed Army Medical Center, Washington, DC

ACADEMIC APPOINTMENTS:

1982–1984 Instructor, Department of Surgery, Uniformed Services University of Health Sciences (USUHS), F. Edward Hebert School of Medicine, Bethesda, MD
1982–1984 Instructor, Department of Surgery, Madigan Army Medical Center, Tacoma, WA
1982–1984 Instructor, Department of Surgery, University of Washington, Seattle, WA
1984–1991 Staff Physician, Department of Surgery, Henry Ford Hospital, Detroit, MI
1984–1993 Clinical Associate Professor of Surgery, University of Michigan, Ann Arbor, MI
1987–1993 Director, Resident Education, Department of Urology, Henry Ford Hospital, Detroit, MI
1988–1991 Director, Urologic Oncology, Department of Urology, Henry Ford Hospital, Detroit, MI
1991–1992 Chief of Urology, Desert Valley Medical Group, Victorville, CA
1992–2000 Associate Professor of Urology, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030
1992–1998 Chief, Division of Urology, Veterans Affairs Medical Center, 2002 Holcombe, Houston, TX 77030
1994–6/2010 Chief, Urology Service, St. Luke's Episcopal Hospital, 6720 Bertner, Houston, TX 77030
1994–08/2000 Director, Education, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030
1995–08/2000 Urology Residency Program Director, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030
07/1996–06/1999 Clinical Assistant Professor of Surgery, Department of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD
05/01/98–08/2000 Interim Chief, Urology Service, The Methodist Hospital, 6565 Fannin, Houston, TX 77030
05/99–06/2008 Medical Director, St. Luke's Episcopal Hospital Cancer Program and the Texas Cancer Institute, 6720 Bertner, Houston, TX 77030

07/1999–06/2006	Adjunct Assistant Professor of Surgery, Department of Surgery, Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD
07/2000–04/2008	Professor of Urology, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030
04/2003–04/2008	Distinguished Cullen Chair in Urology, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, Houston, TX 77030
2006–4/2008	Associate Director for Clinical Affairs, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
04/2008–Present	Clinical Professor of Urology, Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030
01/2008–Present	Medical Director, Robotic Surgery, The Methodist Hospital, 6565 Fannin, Houston, TX 77030
11/2010–Present	Professor of Urology, Weill Cornell Medical College of Cornell University

OTHER PROFESSIONAL EXPERIENCE:

1968–1970 Research Engineer, General Motors Corporation

MILITARY:

1975–1976 Major, Medical Corps Active Duty, Korea
 1976–1978 Pentagon Dispensary
 1982–1984 Staff Urologist, Madigan Army Medical Center, Tacoma, Washington
 1984–1993 U.S. Army Reserve

CERTIFICATION:

1975 National Board of Medical Examiners
 1982 Advanced Trauma Life Support
 1982 Advanced Cardiac Life Support
 1984 American Board of Urology
 1984 Certificate of Competence in Laser Surgery
 1986 Certificate of Competence in Extracorporeal Shock-Wave Lithotripsy
 1990 Certificate of Competence in Laparoscopic Surgery
 1993 Certificate of Competence in Collagen Injection for Urinary Incontinence

MEDICAL LICENSURE:

1976 Commonwealth of Virginia (Inactive)
 1976 State of Michigan (Inactive)
 1976 State of Maryland (Inactive)
 1976 State of Washington (Inactive)
 1977 State of West Virginia (Inactive)
 1992 State of California (Inactive)
 1994 State of Texas

HONORS:

1966 Honors College, Michigan State University
 1967 B.S.E. with Honors, Michigan State University
 1967 Tau Beta Pi Engineering Honorary Society

1968	Fellow, The American Smelting and Refining Corporation, University of Michigan
2000–2014	Listed in <i>America's Top Doctors</i> , published by Castle Connolly Medical, Ltd. (The basis of the national selection process is peer nomination coming from contact by mail, as well as telephone and on-line interviews, with more than 200,000 physicians.)
2001 & 2002	Recognition in <i>The National Registry of Who's Who™</i> , Library of Congress, Washington, DC
2003, 2009 & 2010	Named "Super Doctor" by <i>H Texas</i> magazine. (Nominations are taken from doctors and patients in the Houston area to recognize the top medical professionals in the community for their superior skills, as well as devotion to the medical profession and to the Houston community.)
2004	Named one of "Best Doctors of 2004" ("Super Doctor") by <i>Texas Monthly</i> magazine
2005–2012	Listed in <i>America's Top Doctors for Cancer</i> , a Castle Connolly Guide published by Castle Connolly Medical, Ltd (1 st –7 th Editions)
2005–2014	Selected as a "Texas Super Doctor" by <i>Texas Monthly</i> magazine
2007	Selected by nursing staff to receive the Nurse-Physician Collegiality Award, St. Luke's Episcopal Hospital, Houston, TX
2007	Considered for Inclusion in 2007/2008 Cambridge Who's Who Among Professional Physicians, "Honors Edition" Section of the Registry
2007–2014	Selected to be included in <i>Best Doctors in America 2007–2008, 2009-2010, 2011-2012, 2013-2014</i> database
2009	Consumer Research Council of America Selected in <i>America's Top Urologists Guide</i>
2010	Selected to be included in "The Top Prostate Cancer Specialists" by <i>The New York Time, September 18, 2010</i> .
2011	Selected by the Chief Residents as <i>Volunteer Staff Man of the Year</i> , Baylor College of Medicine, Scott Department of Urology.
2012	Listed in <i>Top Doctors: Southeastern Texas</i> , a Castle Connolly Regional Guide published by Castle Connolly Medical, Ltd (1 st Edition)

PROFESSIONAL SOCIETIES:

1978	American Medical Association
1979	Society of Government Service Urologists
1979	Washington Urologic Society
1979	Association of Military Surgeons
1984	Michigan Branch of American Urological Association
1984	Society of University Urologists
1984	American Urological Association
1985	Fellow, American College of Surgeons
1988	Society of Urologic Oncology
1994	South Central Section, American Urological Association
1995	Harris County Medical Society
1995	Texas Medical Association
1997	Société Internationale d'Urologie
1997	American Society of Clinical Oncology
1999–2007	President, Houston Urological Society
1998	Council of Specialty Societies, Harris County Medical Society
2001	American Society of Gene Therapy

HOSPITAL COMMITTEES:

1986–1988	Pharmacy and Therapeutics, Henry Ford Hospital, Detroit, MI
-----------	---

1986–1989	Credentials Committee, Henry Ford Hospital, Detroit, MI
1987–1989	Laser Task Force, Henry Ford Hospital, Detroit, MI
1988–1989	Human Resources Committee, Henry Ford Hospital, Detroit, MI
1988–1990	Editorial Board, Pacesetter Magazine, Henry Ford Hospital, Detroit, MI
1988–1991	Cancer Coordinating Committee, Henry Ford Hospital, Detroit, MI
1990–1991	Clinical Modalities Review Committee, Henry Ford Hospital, Detroit, MI
1993–2000	Ambulatory Care Committee, Veterans Affairs Medical Center, Houston, TX
1993–2000	Cancer Committee, Veterans Affairs Medical Center, Houston, TX
1994–2000	Physicians' Assistant, Credentialing Committee, Chair, Veterans Affairs Medical Center, Houston, TX
1994–2000	Graduate Medical Education, Baylor College of Medicine, Houston, TX
1994–2011	Medical Executive Committee, St. Luke's Episcopal Hospital, Houston, TX
1994–2011	Quality Assessment Committee, St. Luke's Episcopal Hospital, Houston, TX
1994–2011	Operating Room Committee, St. Luke's Episcopal Hospital, Houston, TX
1994–2011	Cancer Committee, St. Luke's Episcopal Hospital, Houston, TX
1995–2002	Comprehensive Cancer Center Planning Committee, St. Luke's Episcopal Hospital, Houston, TX
1995–1997	Search Committee for Pathology Chairman, St. Luke's Episcopal Hospital, Houston, TX
1995–2003	Board of Directors, McDonald Endowment Fund, St. Luke's Episcopal Hospital, Houston, TX
1997–2000	Continuing Medical Education Committee, The Methodist Hospital, Houston, TX
1998–1999	House Staff Lecture Series Subcommittee, Graduate Medical Education Committee, Baylor College of Medicine, Houston, TX
1999	Executive Committee, The Methodist Hospital, Houston, TX
2004	Search Committee for Hematology/Oncology Chief, Baylor College of Medicine, Houston, TX
2005	Urology Quality Management Committee, St. Luke's Episcopal Hospital, Houston, TX
2005	Chair, Cancer Committee, St. Luke's Episcopal Hospital, Houston, TX
2005	Member, St. Luke's Capital Campaign Committee, Houston, TX
2005	Member, Cancer Center Steering Committee, Baylor College of Medicine, Houston, TX
2010-2012	Member, Urology Peer Review Committee, St. Luke's Episcopal Hospital, Houston, TX
2011-Present	Member, Integrative Medicine Advisory Board, St. Luke's Episcopal Hospital, Houston, TX

NATIONAL COMMITTEES:

1995–1999	Chair, Prostate Cancer Outcomes Research Oversight Task Force, American Urological Association
1997–1999	Consultant to the American Urological Association/American Foundation for Urologic Disease Research Committee
1997–2000	Member, American Urological Association Health Policy Survey and Research Committee, American Urological Association Health Policy Council
1999–2001	Committee on the Economics of Prostate Cancer, World Health Organization
1999–2000	National Clinical Director, Quality Enhancement Research Initiative, National Veterans Affairs System

MICHIGAN STATE MEDICAL SOCIETY:

1987–1991 Education Committee and Research Committee
1987–1991 Legislative Review Committee
1989–1990 Legislation and Regulation Committee
1989–1990 Grants Proposal Committee

MISCELLANEOUS:

1976–1978 Member, Board of Directors, Pentagon Officers Athletic Corps

PROFESSIONAL ACTIVITIES:

1981–1982 Investigator for National Prostate Cancer Project, Walter Reed Army Medical Center, Washington, DC
1986 Investigator, Hybritech Monoclonal Lymphoscintigraphy Study
1987 Consultant Editor, Journal of Urology
1988–1991 Co-Investigator, Diagnosis of Urothelial Tumor Invasion
1990–1991 Co-Investigator, The Role of Specific Genetic Changes and Oncogene Products in the Pathogenesis of Bladder Cancer
1990–1991 Co-Investigator, Photodynamic Therapy in the Treatment of Prostate Cancer
1993–1997 Principal Investigator, Southwest Oncology Group, Baylor College of Medicine, Houston, TX
1994–Present Consultant Editor, *Medical Decision Making* Journal
1994–1998 Director, American Urological Association Outcomes Analysis Task Force
1997–Present Consultant, American Cancer Society, Development of ACS “Screening” Criteria for Prostate Cancer
1997–Present Editorial Advisory Board, *Urology STAT* Newsletter
1998 Clinical Director, Scott Department of Urology “Gene Therapy Program”
1999 U.S. Army Medical Research Command Prostate Cancer Research Program – Peer Reviewer
2000 Principal Investigator, SWOG 9B-12, “Pilot Study of 1-Salenomethionin in Prostate Cancer Patients Scheduled to Undergo Radical Prostatectomy”
2007–Present Member, Pink Ribbons Project Advisory Board
2007–2010 Cancer Liaison Physician for the Cancer Program at St. Luke’s Episcopal Hospital (*Cancer Liaison Physicians are an integral part of cancer programs approved by the American College of Surgeons Commission on Cancer*)

RESEARCH SUPPORT:

AUA Sponsored:

1994–1999 Principal Investigator for Prostate Cancer Patterns of Care Study and Outcomes Analysis Study, \$150,000 per year

Pharmaceutical Grants:

1981–1982 Principal Investigator for Abbott Laboratories’ Prospective Study on Cefsulodin Sodium, a Third-Generation Cephalosporin, \$20,000
1984–1987 Principal Investigator, Norwich Eaton Didronel Study, \$45,000
1987–1989 Principal Investigator, G.H. Besselaar Associates, Anandron Study, \$50,000
1988–1990 Principal Investigator, Schering Corporation, Intron Study Prophylaxis of Superficial Transitional Cell Carcinoma, \$15,000

1988-1989 Principal Investigator, Hoechst-Roussel, Inc., Cefpirome vs. Ceftazidime in Urinary Tract Infections, \$40,000

3/1989-10/1989 Principal Investigator, Hoechst-Roussel, Inc., Cefpirome as a Prophylactic Antibiotic in Urologic Surgery, \$40,000

1989-1990 Co-Principal Investigator, Abbott Laboratories, Hytrin Use in Benign Prostatic Hyperplasia, \$25,000

1993-1996 Suramin in D₃ Adenocarcinoma of the Prostate, Parke-Davis, \$120,000

1993-1995 Principal Investigator, CDDP-e Therapeutic Implant in Localized Carcinoma of the Prostate, Matrix Pharmaceuticals, \$25,000

1994-1997 Co-Investigator, Effect of 13-cis-Retinoic Acid on Recurrent Prostate Cancer Post Radical Prostatectomy. CaP Cure \$50,000

1994-1996 Pfizer Pharmaceutical Corporation; Cardura vs. Hytrin in Treatment of BPH, \$20,000

1995-1996 Principal Investigator, Microwave Therapy for the Management of BPH. Dornier Corporation, \$125,000

1997-1998 Principal Investigator, Liarozole in Hormone-Refractory Prostate Cancer. Janssen Pharmaceutical, \$150,000 (20 patients).

1997-1998 Principal Investigator, Liarozole in Biochemically Recurrent Prostate Cancer. Janssen Pharmaceutical, \$120,000

2011-Present Principal Investigator, Assess Efficacy and Safety of VESicare. Astellas Pharma Global Development, Inc.

NCI Grants:

1984-1987 Principal Investigator, National Prostate Cancer Project, Henry Ford Hospital, \$30,000 per year

1987-1988 Principal Investigator, Urologic Cooperative Oncology Group, \$20,000 per year

1989-1992 Principal Investigator, Henry Ford Hospital, Department of Urology, Southwest Oncology Group, \$30,000 per year

1990-1992 Co-Investigator, Cytogenetic Changes in Transitional Cell Carcinoma of the Bladder. (Principal Investigator, R. Babu, Ph.D.), \$100,000 per year

1993-2000 Principal Investigator, Southwest Oncology Group, Scott Department of Urology, Baylor College of Medicine, \$30,000 per year

1993-1998 Co-Investigator, Houston Health Services Research Program in Prostate Cancer: Familial Patterns in Prostate Cancer. (Principal Investigator, Carol Ashton, M.D.), \$651,366 (total award)

1995-2002 Co-Investigator, NIDDK 1U01DK 49977-01, Medical Therapy in Benign Prostatic Hyperplasia. (Principal Investigator, Kevin M. Slawin, M.D.), \$2.6 million (total award)

1998-1999 Prostate Cancer SPORE, Principal Investigator, Phase I Gene Therapy Protocol

1998-2000 Prostate Cancer SPORE, Principal Investigator, CF4 Administrative Core (\$212,000 per year)

2004-2008 Selenium and Vitamin E Cancer Prevention Trial, Co-Principal Investigator (\$41,000 per year x 7 years)

2001 Hyperbaric Oxygen Therapy with Salvage Prostatectomy, Co-Principal Investigator (\$250,000 x 3 years – applied for)

Other:

1998-2003 Co-Principal Investigator, V.A. Quality Enhanced Research Initiative in Prostate Diseases, \$250,000 per year

1998-2000 McDonald Research Fund (p53 and bladder cancer research), \$50,000

1998-1999 Fleming/Davenport Endowment, \$45,000

1997-2000	Principal Investigator, EDAP Techno-Med, Inc., Evaluation of the Ablathaterm High Intensity Focused Ultrasound Device after Failed Radiation Therapy for Localized Prostate Cancer, \$623,125
2000-2001	The Ethics of Prostate Cancer Screening (McDonald Fund), \$50,000
2003-2007	Co-Investigator, Improving Follow-up of Abnormal PRCA Screening Results, Prostate Cancer Screening Grant, Department of Medicine and Section of Health Services Research, Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center
2011-Present	Principal Investigator, a Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed by Prostatectomy in Patients with High Risk Localized Prostate Cancer.
2011-Present	Co-Investigator, this is a pilot study examining biological endpoints in men with localized prostate cancer who are scheduled to have radical prostatectomies and men with BPH/LUTS following BoNT-A injection. Patients will serve as their own controls by receiving BoNT-A (onabotulinumtoxinA) injections into the right peripheral and transition zones and sham saline injections into the left peripheral and transition zones.
2011-Present	Principal Investigator, a Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of VESicare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy.

JOURNAL EDITORIAL BOARDS:

2005–Present	Editorial Board, <i>Journal of Brachial Plexus and Peripheral Nerve Injury</i>
2006–Present	Consulting Board, Consulting Editor, <i>Journal of Robotic Surgery</i>
2006–Present	Editorial Board, <i>Canadian Journal of Urology</i>
2016–Present	Guest Editor/Reviewer, <i>PLOS One (online journal)</i>

PUBLICATIONS (Peer-Reviewed Journals):

1. Taylor G, McLeod DG, **Miles BJ**, Skoog J: Central neurologic manifestations of adenocarcinoma of the prostate. *Cancer* 53:2728-2730, 1984.
2. **Miles BJ**, Moon MR, Belville WD, Kiesling VJ: Solitary crossed renal ectopia. *J Urol* 133(6):1022-1023, 1985.
3. Mason JC, **Miles BJ**, Belville WD: Urolithiasis and race: Another viewpoint. *J Urol* 134(3):501-502, 1985.
4. **Miles BJ**, Kiesling VJ, Belville WD: Bilateral synchronous simultaneous germ cell tumors. *J Urol* 133(4):679-680, 1985.
5. Fernandez J, **Miles BJ**: Renal carbuncle, a comparison between open and closed [percutaneous] drainage. *Urology* 25(2):142-144, 1985.
6. Shetty PC, Sharma RP, Krasicky GA, Burke MW, Littleton R, **Miles BJ**, Thrall JH, Cerny JC: Percutaneous nephrolithotomy: Current methods and the Henry Ford Hospital experience. *Henry Ford Hospital Med J* 33(2-3):133-137, 1985.
7. **Miles BJ**, Skoog S: Treatment of malakoplakia of the bladder with intravesical Neosporin irrigation. *Urology* 27(1):32-33, 1986.

8. Haas GP, Badalament R, Wonnell DM, **Miles BJ**: Testicular sarcoidosis: Case report and review of the literature. *J Urol* 135(6):1254-1256, 1986.
9. Littleton RH, Cerny JC, **Miles BJ**: Use of occlusion balloon catheter in percutaneous renal stone extraction. *Urology* 27(6):527-528, 1986.
10. Babu VR, Lutz MD, **Miles BJ**, Farah RN, Weiss L, Van Dyke DL: Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. *Cancer Res* 47:6800-6805, 1987.
11. Klutke CG, **Miles BJ**, Obeid F: Unusual presentation of sigmoid diverticulitis as an acute scrotum. *J Urol* 139(2):380-381, 1988.
12. Hafermann MD, Gibbons RP, Murphy GP, Investigator of National Prostatic Project [**Miles BJ**]: Quality control of radiation therapy in multi-institutional randomized clinical trial for localized prostate cancer. *Urology* 31(2):119-124, 1988.
13. McLeod DG, Murphy GP, Priore R, Investigators of National Prostatic Cancer Project [**Miles BJ**]: Comparison of Megace, Stilphostrol, Megace plus DES, or Streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. *Urology* 32:431-436, 1988.
14. Haas GP, Melser M., **Miles BJ**: Method of circumferential pressure dressing of scrotum following bilateral orchiectomy. *Urology* 33(5):429-430, 1989.
15. Babu VR, **Miles BJ**, Cerny JC, Weiss L, Van Dyke DL: Chromosome 21q.22 deletion: A specific chromosome change in a new bladder cancer subgroup. *Cancer Genet Cytogenet* 38(1):127-129, 1989.
16. Crawford D, Eisenberger MA, McLeod DG, *et al.* [**Miles BJ**]: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. *N Engl J Med* 321:419, 1989.
17. Moul JW, **Miles BJ**, Skoog SJ, McLeod DG: Risk factors for perineal seeding of prostate cancer after needle biopsy. *J Urol* 142(1):86-88, 1989.
18. **Miles BJ**, Melser M, Farah R, Markowitz N, Fisher E: The urological manifestations of the acquired immunodeficiency syndrome. *J Urol* 142(3):171-173, 1989.
19. **Miles BJ**, Chapman R, Cerny JC: Adenocarcinoma of the prostate: An overview. *Henry Ford Hospital Med J* 37(1):4, 1989.
20. **Miles BJ**: Screening for adenocarcinoma of the prostate. *Henry Ford Hospital Med J* 37(1):5-7, 1989.
21. **Miles BJ**: Hormonal management of advanced adenocarcinoma of the prostate. *Henry Ford Hospital Med J* 37(1):16-18, 1989.
22. Crissman JD, Zarbo RJ, Johnson T, Babu VR, Sarkar FH, **Miles BJ**, Cerny JC: Advances in the diagnosis of urothelial neoplasia. *Henry Ford Hospital Med J* 37(1):19-23, 1989.
23. Peters JM, **Miles BJ**, Kubus JJ, Crissman JD: Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. *Anal Quant Cytol Histol* 12(5):359-365, 1990.

24. **Miles BJ**, Poffenberger RJ, Farah RN, Moore S: Management of penile gunshot wounds. *Urology* 36(4):318-321, 1990.
25. Babu VR, **Miles BJ**, Cerny JC, Weiss L, Van Dyke DL: Cytogenetic study of four cancers of the prostate. *Cancer Genet Cytogenet* 48(1):83-87, 1990.
26. Peters JM, **Miles BJ**, Kubus JJ, Crissman JD: Prognostic significance of the nuclear DNA content in localized prostatic adenocarcinoma. *Anal Quant Cytol Histol* 12(5):359-365, 1990.
27. Melser M, **Miles BJ**, Kastan D, Shetty PC, Anderson W: Chronic renal failure secondary to post-hysterectomy vaginal prolapse. *Urology* 38(4):361-363, 1991.
28. Sarkar FH, **Miles BJ**, Plieth DH, Crissman JD: Detection of human papillomavirus in squamous neoplasm of the penis. *J Urol* 147(2):389-392, 1992.
29. Crawford ED, Schutz MJ, Clejan S, Drago J, **Miles BJ**: The effect of digital rectal exam on prostate-specific antigen levels. *JAMA* 276:2227-2228, 1992.
30. Telang DJ, **Miles BJ**: Radical surgery in the treatment of localized carcinoma of the prostate. *Henry Ford Hospital Med J* 40(1-2):108-110, 1992.
31. **Miles BJ**, Babiarz J: Maximal androgen ablation: A review. *Henry Ford Hospital Med J* 40(1-2):114-117, 1992.
32. Peters JM, **Miles BJ**, Crissman JD: Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis. *Cancer* 70(5):1159-1165, 1992.
33. Babiarz J, Peters JM, **Miles BJ**, Crissman JD: Comparison of DNA content in primary and lymph node metastases in prostate carcinoma. *Anal Quant Cytol Histol* 15(3):158-164, 1993.
34. Scardino PT, Beck JR, **Miles BJ**: Letter to the Editor regarding Chodak, *et al*: *N Engl J Med* 330(25):1831, June 23, 1994.
35. Beck JR, Kattan MW, **Miles BJ**: Critique of decision analysis for clinically localized prostate cancer. *J Urol* 152:1894, 1994.
36. Korman HJ, Schultz DS, **Miles BJ**, Crissman J, Peabody JO: Proliferating cell nuclear antigen and mutant p53 staining in testicular nonseminomatous germ cell tumor. *J Urol Pathol* 2:1-8, 1994.
37. **Miles BJ**, Kattan MW, Giesler RB, Cowen M: Letter to the Editor re: Krahn *et al*. *JAMA* 273:1173-1174, 1995.
38. **Miles BJ**, Kattan MW: Computer modeling of prostate cancer: A paradigm for oncologic management? *Surg Oncol Clin North Am* 4:361-372, 1995.
39. **Miles BJ**, Carlton CE, Jr: Re: Litwin *et al*. Letter to the Editor, *AUA Today*, pg 11, March 1995.
40. **Miles BJ**, Scardino PT: Physicians, health care costs and total quality management. *J Am College Surg* 180:604-606, May 1995.
41. Dilliogluligil O, **Miles BJ**, Scardino PT: Current controversies in the management of localized prostate cancer. *Eur Urol* 28(2):85-101, August 1995.

42. **Miles BJ**, Scardino PT, Cowen M: A 72-year-old man with localized prostate cancer; Letter to the Editor. *JAMA* 274:1426, 1995.
43. Cowen ME, Kattan MW, **Miles BJ**: Survival and conservative treatment for localized prostate cancer, Letter to the Editor. *JAMA* 275:31, 1996.
44. Kattan MW, Cowen ME, **Miles BJ**: Computer modeling in urology. *Urology* 47:14-21, January 1996.
45. **Miles BJ**: Prostate cancer: Staging and prognosis. *J Urol* 155:1355-1356, April 1996.
46. **Miles BJ**: The management of clinically localized adenocarcinoma of the prostate. *Medical Interface* 9:102-108, May 1996.
47. Schmidt J, Members of the NPCTG [**Miles BJ**]: A randomized blinded prospective trial of Estramustine Sulfate vs. Flutamide in hormone refractory D-2 Ca/P patients. *The Prostate* 28:51-57, 1996.
48. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLenna GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, **Miles BJ**: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. *Urology* 48:47-57, June 1996.
49. Cowen M, **Miles BJ**, Kattan MW: Public attitude about prostate cancer: A survey. *Cancer* 78(9):1952-1957, November 1996.
50. **Miles BJ**, Wheeler T, Scardino PT: Making progress in staging of prostate cancer. *Contemp Urol* 9:25-35, February 1997.
51. Kattan MW, Cowen ME, **Miles BJ**: A decision analysis for treatment of clinically localized prostate cancer. *J Gen Intern Med* 12:299-305, 1997.
52. **Miles BJ**, Kattan MW, Cowen ME: Prostate cancer outcomes analysis. *AUA News* 2(4):21-22, July/August 1997.
53. Gee WF, Holtgrewe L, Albertsen PC, **Miles BJ**, *et al*: Subspecialization, recruitment, and retirement trends of American urologists. *J Urol* 159:509-511, 1998.
54. Cowen ME, **Miles BJ**, Cahill DF, Giesler RB, Beck JD, Kattan MW: The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. *Med Decision Making* 18:376-380, 1998.
55. Gee WF, Holtgrewe HL, Blute ML, **Miles BJ**, Naslund MJ, Nellans RE, O'Leary MP, Thomas R, Painter MR, Meyer JJ, *et al*: 1997 American Urological Association Gallup Survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. *J Urol* 160:1804-1807, 1998.
56. **Miles BJ**: Towards a better crystal ball in prostate cancer prognosis (Editorial). *J Urol* 160:1739-1740, 1998.
57. **Miles BJ**, Giesler B, Kattan MW: Recall and attitudes in patients with prostate cancer. *Urology* 53:169-174, 1999.

58. Kattan MW, Fearn PA, **Miles BJ**, Cowen ME: A note regarding the denominator of the time trade off utility when used to evaluate chronic conditions. *Medical Care* March 1999.
59. Jones JA, Johnston S, Campbell M, **Miles BJ**, Billica R: Endoscopic surgery and telemedicine in microgravity: developing contingency procedures for exploratory class spaceflight. *Urology* 53(5):892-897, 1999.
60. O'Leary MP, Gee William, Holtgrewe HL, Blute ML, Cooper TP, **Miles BJ**, *et al*: 1998 American Urological Association Gallup Survey: Changes in physicians' practice patterns, treatment of ureteral stones and impact of managed care. *J Urol* 162:1702, 1999.
61. Lowentritt BH, Scardino PT, **Miles BJ**, Orejuela FJ, *et al*: Sildenafil citrate as a treatment for erectile dysfunction after radical retropubic prostatectomy. *J Urol* 162:1614, 1999.
62. Kattan MW, Fearn PA, Cantor SB, Hu J, Cowen ME, Giesler RB, **Miles BJ**: Telephone interviews vs workstation sessions for acquiring quality of life data. *AMIA* 23:296-300, 1999.
63. Holtgrewe L, **Miles BJ**, Carlsson P, Nielsen B, Haillet O, Lukacs B, Parsons K: The Economics of Prostate Cancer. Proceedings of World Health Organization 2nd International Consultation on Prostate Cancer, Paris, France, June 1999.
64. Shalev M, **Miles BJ**, Kadmon D, Thompson TC, Ayala G, Butler B, Aguilar E: Suicide gene therapy for prostate cancer using a replication deficient adenovirus containing the herpesvirus thymidine kinase gene. *World J Urol* 18(2):125-129, 2000.
65. Leventis AK, **Miles BJ**, Slawin KM: Diagnosis and management of incidental ureterocele during the treatment of clinically localized prostate cancer. *World J Urol* 18:444-448, 2000.
66. Shalev M, **Miles BJ**, Aguilar-Cordova E, Teh BS, Butler EB, Thompson TC, Herman JR, Adler HL, Scardino PT, Kadmon D: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. *J Urol* 163:1747-1750, 2000.
67. **Miles BJ**: Ability of the 1992 and 1997 American Joint Committee on Cancer Staging System for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. Editorial Comment. *J Urol* 164:89-92, 2000.
68. Ayala G, Wheeler TM, Shalev M, Thompson TC, **Miles BJ**, Kadmon D: Cytopathic effect of *in situ* gene therapy in prostate cancer. *Hum Pathol* 31(7):866-870, 2000.
69. Kernan K, **Miles BJ**: The use of high intensity focused ultrasound in the treatment of prostatic disease. *Proc SPIE* 2000.
70. Gore JL, Shariat SF, **Miles BJ**, Kadmon D, Jiang N, Wheeler TM, Slawin KM.: Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol* 165:1554-1559, 2001.
71. Kim ED, Nath R, Kadmon D, Lipshultz LI, **Miles BJ**, Slawin KM, Tang HY, Wheeler T, Scardino PT: Bilateral nerve grafts during radical retropubic prostatectomy: 1-year follow-up. *J Urol* 165:1950-1956, 2001.
72. Shalev M, Thompson TC, Kadmon D, Ayala G, Kernan K, **Miles BJ**: Gene therapy for prostate cancer. *Urology* 57:8-16, 2001.

73. Kim ED, Nath R, Slawin KM, Kadmon D, **Miles BJ**, Scardino PT: Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. *Urology* 58:983-987, 2001.
74. Thompson TC, Timme TL, Ebara S, Sato T, Yang G, Wang J, **Miles BJ**, Ayala G, Wheeler TM, Kadmon D: *In situ* gene therapy for prostate cancer: immunomodulatory approaches. *Exp Opin Biol Ther* 1:481-495, 2001.
75. Teh BS, Aguilar-Cordova E, Kernan K, Chou CC, Shalev M, Vlachaki MT, **Miles BJ**, Kadmon D, Mai WY, Caillouet J, Davis M, Ayala G, Wheeler T, Brady J, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Butler EB: Phase I/II trial evaluating combined radiotherapy and *in situ* gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. *Int J Rad Oncol Biol Physics* 51:605-613, 2001.
76. **Miles BJ**, Shalev M, Aguilar-Cordova E, Timme TL, Lee HM, Yang G, Adler HL, Kernan K, Pramudji CK, Satoh T, Gdor Y, Ren C, Ayala G, Wheeler TM, Butler EB, Kadmon D, Thompson TC: Prostate-specific antigen response and systemic T cell activation after *in situ* gene therapy in prostate cancer patients failing radiotherapy. *Hum Gene Ther* 12:1955-1967, 2001.
77. Kattan MW, Fearn PA, **Miles BJ**: Time trade-off utility modified to accommodate degenerative and life-threatening conditions. *Proc Am Med Inf Assoc Symp* 304-308, 2001.
78. Au JL, Badalament RA, Wientjes MG, Young DC, Venema P, Lerner SP, **Miles BJ**: Methods to improve the efficacy of intravesical mitomycin C: Results of a phase III trial. *JNCI*, 93:597-604, 2001.
79. Sukin SW, Chhikara M, Zhu X, Ayala G, Aguilar LK, O'Brian Smith E, **Miles BJ**, Thompson TC, Kadmon D, Aguilar-Cordova E: In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. *Mol Ther* 3:500-506, 2001.
80. O'Leary MP, Gee WF, Holtgrewe HL, Blute ML, Cooper TP, **Miles BJ**, *et al.*: 1999 American Urological Association Gallup Survey: Changes in physician practice patterns, treatment of incontinence and bladder cancer and impact of managed care. *J Urol* 164:1311-1316, 2001.
81. Giesler RB, **Miles BJ**, Cowen ME, Kattan MW: Assessing quality of life in men with clinically localized prostate cancer: Development of an improved instrument for use in multiple settings. *Quality of Life Research* 9:645-665, 2001.
82. Mouraviev V, Li L, Tahir SA, Yang G, Timme TL, Goltsov A, Ren C, Satoh T, Wheeler TM, Ittmann MM, **Miles BJ**, Amato RJ, Kadmon D, Thompson TC: The role of caveolin-1 in androgen insensitive prostate cancer. *J Urol* 168:1589-1596, 2002.
83. Shalev M, Mistry S, Kernan K, **Miles BJ**: Squamous cell carcinoma in a female urethral diverticulum. *Urology* 59:773, 2002.
84. Gdor Y, Timme TL, **Miles BJ**, Kadmon D, Thompson TC: Gene therapy for prostate cancer. *Expert Rev Anticancer Ther* 2(3):89-101, 2002.
85. Vicini FA, Martinez A, Hanks G, Hanlon A, **Miles BJ**, Kernan K, Beyers D, Ragde H, Forman J, Fontanesi J, Kestin L, Kovacs G, Denis L, Slawin KM, Scardino PT: An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate cancer based on predefined prognostic categories and minimum follow-up. *Cancer* 95(10):2126-2135, 2002.

86. Bastasch MD, Teh BS, Mai WY, Carpenter LS, Lu HH, Chiu JK, Woo SY, Grant WH III, **Miles BJ**, Kadmon D, Butler EB: Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. *Int J Radiat Oncol Biol Phys* 54(1):101-106, 2002.
87. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai W-Y, Caillouet J, Davis M, **Miles BJ**, Kadmon D, Ayala G, Lu HH, Chiu K, Carpenter LS, Woo SY, Grant WH III, Wheeler T, Thompson TC, Butler EB: Combining radiotherapy with gene therapy (from the bench to the bedside): A novel treatment strategy for prostate cancer. *The Oncologist* 7:458-466, 2002.
88. Cunningham GR, **Miles BJ**: Familial aggregation of prostate cancer in African-Americans and white Americans. *The Prostate* 56:256-262, 2003.
89. Simon MA, **Miles BJ**: Benign fibrous histiocytoma: A rare finding on bone scan staging for prostate adenocarcinoma. *Urol Oncol* 21:45-47, 2003.
90. Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler BE, **Miles BJ**, Amato RJ, Kadmon D, Thompson TC: Therapeutic targets for metastatic prostate cancer. *Curr Drug Targets* 4:251-261, 2003.
91. Teh BS, Aguilar-Cordova E, Aguilar L, Mai W, Caillouet J, Davis M, Vlachaki MT, Kadmon D, **Miles BJ**, Ayala G, Thompson TC, Butler EB: Late toxicity of a phase I/II trial evaluating combined radiotherapy and *in-situ* gene-therapy with or without hormonal therapy in the treatment of prostate cancer. *Int J Radiat Oncol Biol Phys* 57:S275, 2003.
92. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, **Miles BJ**, Slawin KM: Serum BPSA outperforms both total PSA and free PSA as a predictor of prostate enlargement in men without prostate cancer. *Urology* 63(5):905-910, discussion 910-911, May 2004.
93. Singh H, Canto EI, Shariat SF, Kadmon D, **Miles BJ**, Wheeler TM, Slawin KM: Six additional systematic lateral cores enhance sextant biopsy prediction of pathological parameters after prostatectomy. *J Urol* 171(1):204-209, 2004.
94. Singh H, Canto EI, Shariat SF, Kadmon D, **Miles BJ**, Wheeler TM, Slawin KM: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *J Urol* 171(3):1089-1092, 2004.
95. Gdor Y, Timme TL, Kadmon D, **Miles BJ**, Thompson TC: Strategies for prostate cancer gene therapy. *Am J Cancer* 3(2):79-95, 2004.
96. Singh H, Canto EI, Shariat SF, Kadmon D., **Miles BJ**, Wheeler TM, Slawin KM: Predictors of prostate cancer after initial negative systematic 12-core biopsy. *J Urol* 171 (5):1850-1854, 2004.
97. Satoh T, Teh BS, Timme TL, Mai W-Y, Gdor YG, Kusaka N, Fujita T, Pramudji CK, Vlachaki MT, Ayala G, Wheeler T, Amato R, **Miles BJ**, Kadmon D, Butler EB, and Thompson TC: Enhanced systemic T-cell activation after *in situ* gene therapy with radiotherapy in prostate cancer patients. *Intl J Radiat Oncol Biol Phys* 59:562-571, 2004.
98. Canto E, Singh H, Shariat SF, Kadmon D, **Miles BJ**, Slawin KM: Effects of systematic 12-core biopsy on the performance of percent free PSA for prostate cancer detection. *J Urol* 172(3):900-904, 2004.
99. Mistry S, **Miles BJ**, Lipshultz LI: Use of continuous local anesthetic infusion pumps in urologic surgery. *Contemp Urol* 16:12-13, 2004.

100. Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, **Miles BJ**, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB: Phase I/II trial evaluating combined intensity-modulated radiotherapy and *in situ* gene therapy with or without hormonal therapy in treatment of prostate cancer – Interim report on PSA response and biopsy data. *Int J Radiat Oncol Biol Phys* 58(5):1520-1529, April 1, 2004.
101. Li L, Ittmann MM, Ayala G, Tsai M-J, Amato RJ, Wheeler TM, **Miles BJ**, Kadmon D, Thompson TC: The emerging role of the PI3-K-Akt pathway in prostate cancer progression. *Prostate Cancer & Prostate Diseases*, 8(2):108-118, 2005.
102. Shariat SF, Andrews B, Anwuri VA, Naderi ASA, **Miles BJ**, Roth D, Wheeler TM, Slawin KM: Anomalies of the Wolffian duct derivatives encountered at radical prostatectomy. *Reviews in Urology* 7:75-80, 2005.
103. Subramanian VS, Coburn M, **Miles BJ**: Carcinosarcoma of the prostate with multiple metastases: Case report and review of literature. *Urol Onc* 23(3):181-183, May-June 2005.
104. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, **Miles BJ**, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB: Expanding the therapeutic index of radiation therapy by combining *in situ* gene therapy in the treatment of prostate cancer. *Technol Cancer Res Treat* 5(1):23-26, 2006.
105. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, **Miles BJ**, Rauen K, Teh B, Butler EB, Thompson TC, Kadmon D: Biological response determinants in HSV-*tk*+ganciclovir gene therapy for prostate cancer. *Mol Ther* 13:716-728, 2006.
106. Crawford ED, Schultz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella Austenfeld LG, Stone NN, **Miles BJ**, *et al*: The effect of digital rectal examination on prostate-specific antigen levels. *JAMA* 267:2227-2228, 2006.
107. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, **Miles BJ**, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM: Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine. A Southwest Oncology Group Study. *Clin Can Res* 12(7 Pt 1):2178-84, Apr 2006.
108. Tahir SA, Frolov A, Hayes TG, Mims MP, **Miles BJ**, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D: Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. *Clin Cancer Res* 12(16):4872, Aug 2006.
109. **Miles BJ**, Khera M: Can preoperative behavioral training reduce postprostatectomy incontinence? *Nat Clin Pract Urol* 3(6):302-303, Jun 2006.
110. Ayala G, Li R, Yan J, Deng Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch GR, Frolov A, **Miles BJ**, Wheeler TM, Harper JW, Tsai M-J, Ittmann M, Kadmon D. Bortezomib mediated inhibition of SRC-3 degradation leads to activated Akt in a neoadjuvant prostate cancer trial. *N Engl J Med* 2007.
111. Teh BS, Bastasch MD, Mai WY, Kadmon D, **Miles BJ**, Butler EB: Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. *Am J Clin Oncol* 30(4):395-400, Aug 2007.
112. Yang G, Addai J, Wheeler TM, Frolov A, **Miles BJ**, Kadmon D, Thompson TC: Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. *Hum Pathol* 38(11):1688-695, Nov 2007.

113. Yanagisawa N, Li R, Rowley D, Hao L, Kadmon D, **Miles BJ**, Wheeler TM, Ayala G: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. *Hum Pathol* 38:1611-1620, Nov 2007; Reprint 39:282-291, Feb 2008.
114. Volk RJ, Jibaja-Weiss ML, Hawley ST, Kneuper S, Spann SJ, **Miles BJ**, Hyman DJ: Entertainment education for prostate cancer screening: a randomized trial among primary care patients with low health literacy. *Patient Edu Couns*. 73:482-489, Dec 2008.
115. Ayala, G, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson TC, **Miles BJ**, Ittmann MM, Rowley D: Cancer-related axonogenesis and neurogenesis in prostate cancer. *Clin Cancer Res* 14(23):7593-7603, December 1, 2008.
116. Mistry S, Mayer WA, Khavari R, Ayala G, Miles BJ: Who's too old to screen: Prostate cancer in elderly men. *Can Urol Assoc J.*, June 2009, 3(3): 205-210.
117. Parker PA, Pettaway CA, Babaian RJ, Pisters LL, **Miles B**, Fortier A, Wei Q, Carr DD, Cohen L: The effects of a presurgical stress management intervention for men with prostate cancer undergoing radical prostatectomy. *J Clin Oncol* 27(19):3169-76, Jul 2009.
118. Khavari R, Stamatakis L, **Miles B**: Robot-assisted laparoscopic prostatectomy performed in a patient with severe thrombocytopenia due to primary myelofibrosis. *Can Urol Assoc J* 3(4):E23-E24, Aug 2009.
119. Joseph RA, Goh AC, Cuevas SP, Donovan MA, Kauffman MG, Salas NA, **Miles B**, Bass BL, Dunkin BJ: "Chopstick" surgery: a novel technique improves surgeon performance and eliminates arm collision in robotic single-incision laparoscopic surgery. *Surg Endosc* 24(6):1331-1335, Jun. 2010.
120. Moskovic DJ, Mohamed O, Sathyamoorthy K, **Miles BJ**, Link RE, Lipshultz LI, Khera M: The female factor: Predicting compliance with post-prostatectomy erectile preservation programs. *J Sexual Medicine* 7(11):3659-3665, Nov 2010.
121. Ayala GE, Muezzinoglu B, Hammerick KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, **Miles BJ**, Wheeler TM, Rowley DR: Determining prostate cancer specific death through quantitation of stromogenic carcinoma area in prostatectomy specimens. *American Journal of Pathology* 178(1): 79-87, January 2011.
122. Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, Babaian R, Pisters L, **Miles B**, Wei Q, Wiltz L, Patel T, Radvanyi L: Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. *Psychosom Med* 73(3):218-25, April 2011.
123. Moskovic DJ, Mohamed O, Sathyamoorthy K, **Miles BJ**, Link RE, Lipshultz LI, Khera M: Emerging Concepts in Erectile Preservation Following Radical Prostatectomy: A Guide For Clinicians. *Int'l Journal of Impotence Research*, online pub, June 23, 2011; doi:10.1038/ijir.2011.26
124. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, **Miles BJ**, Kadmon D: GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy. *Clin Cancer Res*. 17(22):7174-82, Nov. 2011.

125. Goh AC, Goldfarb DW, Sander JC, **Miles BJ**, Dunkin BJ: Global Evaluative Assessment of Robotic Skills: Validation of a Clinical Assessment Tool to Measure Robotic Surgical Skills. *J Urol.* Jan 2012;187(1):247-52.
126. Stamatakis L, Cheng PJ, Ho PL, Thrall MJ, Mayer WA, **Miles BJ**, Link RE: A 60-Year-Old Woman with an Incidentally Discovered Right Renal Mass. *Urology.* Dec 2012;80(6): 1183-6
127. Ding Y, He D, Florentin D, Frolov A, Hilsenbeck SG, Ittmann MM, Kadmon D, **Miles B**, Rowley DR, Ayala GE: Semaphorin 4F as a Critical Regulator of Neuro-Epithelial Interactions and a Biomarker of Aggressive Prostate Cancer. *Clin Cancer Res.* Oct 4, 2013.
128. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Lui JS, **Miles BJ**, Lipshultz LI, Khera M: Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy. *J Urol.* Aug 2013;190(2):639-44.
129. Lyons C, Goldfarb D, Jones SL, Badhiwala N, **Miles B**, Link R, Dunkin BJ: Which Skills Really Matter? Proving Face, Content, and Construct Validity for a Commercial Robot. *Surg Endosc.* June 2013;27(6):2020-30.
130. Pastuszak AW, Pearlman AM, Godoy G, **Miles BJ**, Lipshultz LI, Khera M: Testosterone Replacement Therapy in the Setting of Prostate Cancer Treated with Radiation. *Int J Impot Res.* Jan 2013;25(1):24-28
140. Miyai K, Divatia MK, Shen SS, **Miles BJ**, Ayala AG, Ro JY. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. *Hum Pathol.* 2014 Apr 12. pii: [Epub ahead of print] PMID: 24842280
141. Miyai K, Divatia MK, Shen SS, **Miles BJ**, Ayala AG, Ro JY. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. *Int J Clin Exp Pathol.* 2014 Apr 15;7(5):2518-26. eCollection 2014. PMID: 24966964
142. Miyai K, Kristiansen A, Egevad L, Pina-Oviedo S, Divatia MK, Shen SS, **Miles BJ**, Ayala AG, Park YW, Ro JY. Seminal vesicle intraepithelial involvement by prostate cancer: putative mechanism and clinicopathological significance. *Hum Pathol.* 2014 May 23. [Epub ahead of print] PMID: 24993314
143. Bianco FJ, Albala DM, Belkoff LH, **Miles BJ**, Peabody JO, He W, Bradt JS, Haas GP, Ahlering TE. A Randomized, Double-Blind, Solifenacin Succinate versus Placebo Control, Phase 4, Multicenter Study Evaluating Urinary Continence after Robotic Assisted Radical Prostatectomy. *J Urol.* 2014 Oct 2. [Epub ahead of print] PMID: 25281778
144. Okoye E, Choi EK, Divatia M, **Miles BJ**, Ayala AG, Ro JY. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature. *Int J Clin Exp Pathol.* 2014 Dec 1;7(12):9061-6. PMID: 25674288
145. Goh AC, Aghazadeh MA, Krasnow RE, Pastuszak AW, Stewart JN, **Miles BJ**. Robotic Intracorporeal Continent Cutaneous Urinary Diversion: Primary Description. *J Endourol.* 2015 Jan 5. [Epub ahead of print] PMID: 25556514

- 146 Kim MJ, Divatia MK, Lee JH, Shen S, **Miles BJ**, Hwang JH, Ayala AG, Ro JY. Collagenous micronodules in prostate cancer revisited: are they solely associated with Gleason pattern 3 adenocarcinomas? *Int J Clin Exp Pathol*. 2015 Apr 1;8(4):3469-76. eCollection 2015. PMID: 26097531
- 147 Aghazadeh MA, Mercado MA, Pan MM, **Miles BJ**, Goh AC. Performance of Robotic Simulated Skills Tasks is Positively Associated with Clinical Robotic Surgical Performance. *BJU Int*. 2016 Apr 22. [Epub ahead of print] PMID: 27104883

SUBMITTED/ACCEPTED FOR PUBLICATION (Peer-Reviewed Journals):

1. Florentin D, Ding Y, He D, Ragheb A, Creighton CJ, Frolov A, Dakhova O, Zhang Y, Smith C, Kadmon D, **Miles BJ**, Ittmann M, Rowley D, Ayala G: Influence of the Neural Microenvironment on Prostate Cancer. *PLOS Med* (Submitted, Nov 2013).
2. Ro J, Ayala A, Shen S, Divatia MK, Miles BJ: Heterogeneous Clinicopathological Features of Intraductal Carcinoma of the Prostate: a Comparison between “Precursor-like” and “Regular type” Lesions. (Submitted, 2014).

PUBLISHED ARTICLES (Non-Peer-Reviewed):

1. **Miles BJ**, Kattan MW: Computer modeling of prostate cancer treatment: A paradigm for oncologic management? *AUA Today*, 8:24-26, 1995.
2. Beck JR, Kattan MW, **Miles BJ**: Decision analysis is a useful tool. *AUA Today*, 8:26-27, 1995.
3. **Miles BJ**: Prostatic disease: Insights and innovations. *CME Monograph*, Discovery International, pp 99-106, Jan 1997.
4. Kattan MW, Giesler RB, Cowen ME, **Miles BJ**: Utility assessment in outcomes research. *AUA Today*, Sept 1997.
5. Giesler RB, Kattan MW, Cowen ME, **Miles BJ**: Quality of life: What is it and why should we care? *AUA Today*, Mar 1998.
6. Schatte EC, **Miles BJ**: Bone scans in patients with prostate cancer – Why and when? *AUA News*, pp 30-34, Nov/Dec 1998.
7. Scardino PT, Carroll P, **Miles BJ**, deKernion J: Prostate cancer treatment, stage by stage. *Urology News*, Dec 1996.
8. **Miles BJ**, Schatte EC: Disease staging in patients with newly diagnosed prostate cancer: Current management. *Urology Index & Reviews*, II:3-5, 1999.
9. Carson C, Djavan B, Manyak M, McVary K., **Miles BJ**: The evolution of microwave thermotherapy for BPH. *Urologix Roundtable Discussion Series*, Summer 2003.
10. Mistry S, **Miles BJ**, Lipshultz LI: Surgeon’s Corner: Use of continuous local anesthetic infusion pumps in urologic surgery. *Contemp Urol* 16(10):12–13, Oct 2004.

11. Volk R, Kneuper S, Spann S, Hawley S, **Miles BJ**: Promoting engagement in prostate cancer screening decision making using entertainment education with patients of limited health literacy. *Society of Medical Decision Making*, Oct 2006.
12. Khavari R, Stamatakis L, **Miles BJ**: Robot-assisted laparoscopic prostatectomy performed in a patient with severe thrombocytopenia due to primary myelofibrosis. *Can Urol Assoc J*. 3:E23-E24 2009.

IN PREPARATION:

1. Kadmon D, Shariat S, Karakiewicz P, Nath R, **Miles BJ**, Kim ED, Gore JL, Slawin KM: Unilateral interposition sural nerve grafting following ipsilateral neurovascular bundle resection at radical prostatectomy (RP) decreases the time to potency recovery.
2. Anwuri VA, Naderi A, Shariat SF, **Miles BJ**, Roth D, Wheeler TM, Slawin KM: Wolffian duct derivative anomalies encountered at radical prostatectomy.

BOOK CHAPTERS:

1. **Miles BJ**: Impact of therapy on adenocarcinoma of the prostate. *Proceedings of the Royal College of Surgeons*: In: *Epidemiology of Prostate Disease*. Edited by Garraway. London, England: Springer, 1995, pp 239-247.
2. Reiter RE, Scardino PT, **Miles BJ**: Salvage radical prostatectomy for local recurrence of prostate cancer after radiation therapy. In: *Comprehensive Textbook of Genitourinary Oncology*. Edited by NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey. Baltimore: Williams & Wilkins Publishers, 1996, pp 817-828.
3. Beck JR, Kattan MW, **Miles BJ**: Quantitative approaches to diagnostic testing and decision making in genitourinary oncology. In: *Comprehensive Textbook of Genitourinary Oncology*. Edited by NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey. Baltimore: Williams & Wilkins Publishers, 1996, pp 21-32.
4. **Miles BJ**: Does a Positive PSA and PSM RT-PCR assay indicate micrometastatic disease? In: *Podium Urologie*. Edited by Fahlenkamp, Loening, Mansson, Ringert. Berlin, Germany: Blackwell Publishers, 1996, pp 53-56.
5. **Miles BJ**: Salvage surgery after radiation therapy in prostate cancer. In: *Podium Urologie*. Edited by Fahlenkamp, Loening, Mansson, Ringert. Berlin, Germany: Blackwell Publishers, 1996, pp 199-201.
6. **Miles BJ**: Goals of treatment in stage T3 (c) cancer patients. Is expectant management ethical? In: *Podium Urologie*. Edited by Fahlenkamp, Loening, Mansson, Ringert. Berlin, Germany: Blackwell Publishers, 1996, pp 253-255.
7. **Miles BJ**, Sirls L: Electrovaporization of the prostate. In: *Textbook of Benign Prostatic Hyperplasia*. Edited by Kirby, McConnell, Fitzpatrick, Roehrborn, Boyle. London, England: Isis Publishers, 1996, pp 463-469.
8. **Miles BJ**, Kattan MW: Decision analysis: Prostate cancer PORT. In: *Cancer Policy*. Norwell, Massachusetts: Klawer Academic Publishers, 1998.

9. **Miles BJ**, Kattan MW: Treatment options for clinically localized prostate cancer. In: *Current Medicine*, 1998.
10. Kattan MW, **Miles BJ**: The patient's choice of surgery for clinically localized prostate cancer. In: *Atlas of Clinical Urology*. Edited by ED Vaughan, Jr, AP Perlmutter, JD McConnell, PT Scardino. London: Churchill Livingstone, The Prostate; vol II, 1999, pp 9.1-9.7.
11. **Miles BJ**, Herman JR: Salvage prostatectomy for localized radio-recurrent prostate cancer. In: *Comprehensive Textbook of Genitourinary Oncology*, 2nd Edition. Edited by ENJ Vogelzang, PT Scardino, DS Coffee, **BJ Miles**. Philadelphia: Lippincott Williams and Wilkins Publishers, 2000, pp 813-823.
12. Beck JR, Kattan MW, **Miles BJ**: Quantitative approaches to diagnostic testing and decision making in genitourinary oncology. In: *Comprehensive Textbook of Genitourinary Oncology*, 2nd Edition. Edited by NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey. Philadelphia: Lippincott Williams & Wilkins Publishers, 2000, pp 22-32.
13. Schatte E, Fradet Y, **Miles BJ**: Epidemiology of bladder cancer. In: *Comprehensive Textbook of Genitourinary Oncology*, 2nd Edition. Edited by NJ Vogelzang, PT Scardino, DS Coffee, **BJ Miles**. Philadelphia: Lippincott Williams & Wilkins Publishers, 2000, pp 282-288.
14. **Miles BJ**: Radical retropubic prostatectomy for T1b–T2b prostate cancer. In: *Advanced Therapy of Prostatic Disease*. BC Decker Publishers, March 2000.
15. **Miles BJ**: Case study of combined gene and radiation therapy as an approach in the treatment of cancer. In: *Gene Therapy of Cancer*, 2nd Edition. Edited by EC Lattime, SL Gerson. San Diego: Academic Press, 2002.
16. **Miles BJ**, Kernen K: Transurethral vaporization of the prostate. In: *eMedicine: Emergency Medicine*. Boston: eMedicine Corporation, 2004.
17. Bird E, Herman J, **Miles BJ**: Surgery of the genitourinary system. In: *Surgery – Logic, Workup and Treatment*. Philadelphia: WB Saunders Company, 2004.
18. **Miles BJ**, Cornell R: Surgery of the adrenal gland. In: *eMedicine: Emergency Medicine*. Boston: eMedicine Corporation, 2004.
19. **Miles BJ**, Shalev M: Open prostatectomy for benign prostatic hyperplasia. In: *eMedicine: Emergency Medicine*. Boston: eMedicine Corporation, 2004.
20. Kattan MW, **Miles BJ**: Decision making for clinically localized prostate cancer. In: *Atlas of the Prostate*. Edited by PT Scardino, KM Slawin. Philadelphia: Current Medicine LLC, 2006, pp 137-144.
21. Timme TL, Fujita T, Wang H, Naruishi K, Kadmon D, Amato RJ, **Miles BJ**, Ayala G, Wheeler TM, Teh BS, Butler EB, Thompson TC: Cytokine gene therapy for genitourinary cancer. Chapter 14. In: *Cancer Drug Discovery and Development: Gene Therapy for Cancer*. Edited by KK Hunt, S Vorburger, SG Swisher. Totowa, NJ: Humana Press, Inc, 2007, pp 223–241.
22. M.K. O'Malley, O. Celik, J.C. Huegel, M.D. Byrne, J. Bismuth, B. Dunkin, A. Goh, and B. Miles, Robotics as a Tool for Training and Assessment of Surgical Skill. *Computational Surgery and Dual*

Training: Computing, Robotics, and Imaging, Marc Garbey, Barbara Lee Bass, Scott Berceli, Christophe Collet, and Pietro Cerveri (Eds.), Springer New York, pp. 365-375, 2014.

IN PRESS/SUBMITTED (Book Chapters): Not applicable.

BOOKS AND JOURNALS (Edited):

1. Comprehensive Textbook of Genitourinary Oncology. Eited by NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey, **BJ Miles**. Williams & Wilkins, Baltimore, MD, 1996.
2. Guest Reviewer, Medical Decision Making, 1994 and 1995.
3. Guest Editor, Year Book of Urology, Mosby-Year Book Inc., Chicago, Illinois, 1995 and 1996.
4. Guest Reviewer, Journal of Urology, 1995-2004.
5. Guest Reviewer, Urology, 1996-2004.
6. Guest Reviewer, Cancer, 1996, 1997, and 1998.
7. Guest Reviewer, Lancet, 1998.
8. Urology STAT Newsletter, Editor, 1998.
9. Urology Index and Reviews (Lippincott), Editor, 1998.
10. Comprehensive Textbook of Genitourinary Oncology, 2nd Edition. Edited by NJ Vogelzang, PT Scardino, DS Coffee, **BJ Miles**. Philadelphia: Lippincott Williams and Wilkins Publishers, 2000.

ABSTRACTS:

1. Mansdorf SZ, **Miles BJ**: A protective dermal film, Industrial Hygiene, 1978.
2. **Miles BJ**, McLeod DG: Neurologic manifestations of metastatic adenocarcinoma of the prostate. Annual Meeting of the American Urological Association, Kansas City, Kansas, 1982 (Presented by Dr. Miles).
3. Cerny JC, **Miles BJ**, Haas G: Radical prostatectomy vs. interstitial I-125 radiation for adenocarcinoma of the prostate. Annual Meeting of the American Urological Association, Atlanta, Georgia, 1985.
4. Babu VR, Van Dyke DC, **Miles BJ**, Lutz M, Weiss L: Nonrandom chromosome changes in transitional cell carcinoma of the bladder. Clinical Research, 34(1), 1986.
5. **Miles BJ**, Lutz M, Babu VR: Cytogenetics of transitional cell carcinoma of the bladder. Annual Meeting of the American Urological Association, New York, NY, 1986 (Presented by Dr. Miles).
6. **Miles BJ**, Lutz M, Babu VR: Cytogenetics of transitional cell carcinoma of the bladder. American Urological Association, North Central Section, Palm Springs, CA, 1986 (Presented by Dr. Miles).

7. **Miles BJ**, MacIntyre RC, Peron SE, Madrazo B, Cerny JC: Ultrasound guided needle biopsy of the prostate gland. American Urological Association, North Central Section, Palm Springs, CA, 1986 (Presented by Dr. Miles).
8. Babu VR, Lutz MD, Van Dyke DL, **Miles BJ**, Weiss L: Transitional cell carcinoma of the bladder: Cytogenetics, Histopathology, and Tumor Behavior. American Society of Human Genetics, 1986.
9. **Miles BJ**, Golden J, Michael F, Petrozzi C: Disseminated intravesicular coagulation in metastatic prostate carcinoma. American College of Physicians National Meeting, 1986.
10. Babu V, **Miles BJ**, Lutz MD, Van Dyke DL, Weiss L: Transitional cell carcinoma of the bladder marker chromosomes and their prognostic value. Second International Conference on Chromosomes in Solid Tumors, Tucson, Arizona, January 1987.
11. **Miles BJ**, Melser M, Farah RN: Urologic manifestations in AIDS. Annual Meeting of the American Urological Association, Anaheim, CA, 1987 (Presented by Dr. Miles).
12. Babu VR **Miles BJ**, Lutz MD, Van Dyke DL, Weiss L: Transitional cell carcinoma of the bladder: Cytogenetics, Histopathology and Tumor Behavior. 25th Somatic Cell Genetics Conference, Santa Fe, NM, January 1987.
13. **Miles BJ**, Littleton RH, Sirls L: The necessity of orchiectomy after hormonal failure with LHRH analogs. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988 (Presented by Dr. Miles).
14. **Miles BJ**, Cerny JC, Schervish EW: I-125 implants in the management of localized prostatic carcinoma. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988.
15. Poffenberger R, **Miles BJ**, Farah RN: Management of penile gunshot wounds. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988.
16. Liu BC, **Miles BJ**, Cerny JC, deKernion J, Zarbo R: Detection of urothelial neoplastic cells using monoclonal E7. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988.
17. **Miles BJ**, Farah RN, Melser M: Urologic manifestations of AIDS. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988 (Presented by Dr. Miles).
18. Schmidt JD, Gibbons RP, Bartolucci A, Murphy GP, Investigator of the National Prostatic Cancer Treatment Group, [**Miles BJ**]: Prognosis in stage D-1 prostate cancer relative to anatomic sites of nodal metastases. Annual Meeting of the American Urological Association, Boston, Massachusetts, 1988.
19. **Miles BJ**, Crissman JD, Liu BS, Zarbo RJ, Johnson TL, Babu VR, Cerny JC: Diagnosis of urothelial neoplasia. Society for Analytical Cytology, 1988.
20. **Miles BJ**, Babu VR, Cerny JC, Crissman JD, Weiss L, Van Dyke DL: A prospective study of 92 bladder cancer patients: Cytogenetics, Histopathology, and Tumor Behavior. American Society of Human Genetics, 1988.
21. **Miles BJ**, Cerny JC, Liu BS, Zarbo RJ, Johnson TL, Crissman JD: Diagnosis of urothelial neoplasia. Society for Analytical Cytology, Breckenridge, Colorado, September 1988.

22. Liu BS, Zarbo RJ, Crissman JD, **Miles BJ**, Cerny JC: Detection of Urothelial Neoplastic Cells Using Monoclonal E7. Society for Analytical Cytology, Breckenridge, Colorado, September 1988.
23. Johnson TL, Liu BC, Crissman JD, Zarbo RJ, **Miles BJ**, Foster C: Cell surface expression of ras-oncogene product and T-antigen in transitional cell carcinoma of the bladder. 36th Meeting of the American Society of Cytology, September 1988.
24. Wonnell D, Bricker L, **Miles BJ**, Bae Y, Cerny JC: Treatment of locally advanced transitional cell carcinoma with irradiation of concomitant 5-fluorouracil infusion. American Urological Association, North Central Section, Orlando, FL, November 1988.
25. Peabody J, **Miles BJ**, Cerny JC, Liu BS, Zarbo RJ, Johnson TL, Crissman JD: Diagnosis of urothelial neoplasia. American Urological Association, North Central Section, Orlando, FL, November 1988 (Presented by Dr. Miles).
26. Schervish E, **Miles BJ**, Cerny JC, Crissman JD, Johnson TL: Flow cytometry and cytology in transitional cell carcinoma of the bladder. American Urological Association, North Central Section, Orlando, FL, November 1988.
27. Peabody J, **Miles BJ**, Cerny JC, Liu BC, Zabo R, Johnson TL, Crissman JD: Diagnosis of urothelial neoplasia. Annual Meeting of the American Urological Association, Dallas, TX, April 1989.
28. Cerny JC, **Miles BJ**, Crissman JD: Comparison of DNA analysis of urothelial neoplasia and bladder washes. Annual Meeting of the American Urological Association, Dallas, TX, April 1989.
29. Wonnell Bricker L, **Miles BJ**, Cerny JC: Treatment of locally advanced transitional cell carcinoma with irradiation of concomitant 5-FU. Annual Meeting of the American Urological Association, Dallas, TX, April 1989.
30. Peters JM, Crissman J, Cerny JC, **Miles BJ**: Prognostic significance of nuclear DNA content using image analysis in prostatic carcinoma. Annual Meeting of the American Urological Association, Dallas, TX, April 1989.
31. **Miles BJ**, Cerny JC, Zarbo R, Crissman JD: DNA content and cytogenetic analysis of urothelial neoplasia. Annual Meeting of the American Urological Association, Dallas, TX, April 1989 (Presented by Dr. Miles).
32. Van Dyke DL, Warsham MJ, Babu VR, Benninger M, **Miles BJ**: Cytogenetics of five squamous cell carcinomas. Am Soc Hum Genet, June 1989.
33. Peters JM, **Miles BJ**, Crissman JD: Prognostic significance of nuclear DNA content in localized prostatic adenocarcinoma using image analysis. Annual Meeting of the American Urological Association, New Orleans, LA, May 1990.
34. Kirkemo AK, **Miles BJ**, Peters JM: Use of amitriptyline in interstitial cystitis. Annual Meeting of the American Urological Association, New Orleans, LA, May 1990.
35. Babiarz J, Peters JM, Crissman JD, **Miles BJ**: DNA quantitation in prostatic adenocarcinoma: A comparison between primary tumor and lymph node metastasis. Annual Meeting of the American Urological Association, Toronto, Canada, 1991.

36. Sirls LT, **Miles BJ**, Babu VR: Chromosomal changes in transitional cell carcinoma of the bladder. Annual Meeting of the American Urological Association, Toronto, Canada, 1991 (Presented by Dr. Miles).
37. Peters JM, **Miles BJ**, Cerny JC, Crissman JD: DNA quantitation in stage D prostate adenocarcinoma metastases. Annual Meeting of the American Urological Association, Toronto, Canada, 1991.
38. Crawford ED, Schultz M, Drago J, Resnick MI, **Miles BJ**: The effect of digital rectal examination on PSA. Annual Meeting of the American Urological Association, Toronto, Canada, 1991.
39. Babiarz J, Peabody J, **Miles BJ**, Cerny JC: The association of acquired renal cystic disease with renal cell carcinoma in patients on chronic ambulatory peritoneal dialysis. Annual Meeting of the American Urological Association, Washington, DC, 1992.
40. Kattan MW, **Miles BJ**, Goto Y, Scardino PT: CART vs. logistic regression in the prediction of clinically important prostate cancer. Medical Decision Making Journal, 1995.
41. Kalns JE, Wientjes MG, Badalament RA, Burgers JK, Jessie L, Lerner SP, **Miles BJ**, Dinney CPN, Venema PL, Farah RN, Haas GP, Klein EA, Lamm DL: Pharmacokinetic interventions to improve intravesical therapy of superficial bladder cancer. Annual Meeting of the American Urological Association, Las Vegas, Nevada, 1995.
42. Kondylis FI, **Miles BJ**, Scardino PT: Prostatic acid phosphatase and surgical management of prostate cancer. Annual Meeting of the American Urological Association, Las Vegas, Nevada, 1995.
43. Reiter RE, Wheeler T, Carlton CE, Scardino PT, **Miles BJ**: Radical perineal vs. retropubic prostatectomy in clinical T1C prostate cancer. Annual Meeting of the American Urological Association, Las Vegas, Nevada, 1995.
44. Cowen M, Kattan M, Cahill D, **Miles BJ**: The value or utility of prostate cancer states. Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.
45. Bostwick DG, Wheeler TM, Barrett DM, Scardino PT, **Miles BJ**: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996 (Presented by Dr. Miles).
46. **Miles BJ**, Kattan MW, Scardino PT, Wheeler TM, deVere White R, Gandour-Edwards R, Humphrey PA, Hudson MA, Fradet Y, Mahran HE, Bostwick DG: Optimized microvessel density is associated with recurrence. Annual Meeting of the American Urological Association, New Orleans, LA, April 12-17, 1997.
47. Kattan MW, Cowen ME, **Miles BJ**, Beck JR: Modeling the impact of comorbidity on the decision to treat clinically localized prostate cancer. Annual Meeting of the American Urological Association, New Orleans, LA, April 12-17, 1997.
48. Green LK, Kota RK, **Miles BJ**: The cost-effectiveness of bladder washing cytologic examination in asymptomatic microscopic hematuria. Annual Meeting of the United States and Canadian Academy of Pathology, 1997.
49. **Miles BJ**: Faculty member – Current health utility of newly diagnosed prostate cancer patients. Annual Meeting of the American Urological Association, San Diego, CA, May 30 – June 4, 1998.

50. **Miles BJ:** Inaugural National Meeting of the Genito-Urinary Oncology Group, Sydney, New South Wales, July 25-27, 1997.
 - a. The Baylor experience with radical prostatectomy
 - b. A cost analysis of prostate cancer management in the USA
 - c. The Baylor Department of Urology prostate cancer gene therapy experience
51. **Miles BJ:** 5th Innovations in Urologic Practice, Scott Department of Urology, Baylor College of Medicine, Santa Fe, NM, September 25-27, 1997.
 - a. Neo-adjuvant and adjuvant therapy for locally advanced disease
 - b. New horizons in the management of metastatic prostate cancer
52. **Miles BJ:** Faculty: 7th Annual Genitourinary Conference. Status of Baylor Clinical Gene Therapy Trial, Houston, TX, February 18-19, 1999.
53. **Miles BJ:** Course Instructor: 94th Annual Meeting of the American Urological Association. The Treatment of Metastatic Prostate Cancer, Dallas, TX, April 30 – May 6, 1999.
54. **Miles BJ:** 6th Innovations in Urologic Practice, Scott Department of Urology, Santa Fe, NM, September 24, 1999.
 - a. The changing role of hormonal therapy for managing prostate cancer patients
 - b. Gene therapy for prostate cancer: What have we learned and where are we headed
55. **Miles BJ:** Cancer care; quality of life and outcomes symposium: the value or utility of prostate cancer states. Chicago, IL, November 14, 1998.
56. Holtgrew L, **Miles BJ**, Carlsson P, Nielsen B, Haillet O, Lukacs B, Parsons K: The economics of prostate cancer. World Health Organization 2nd International Consultation on Prostate Cancer. Paris, France, June 28, 1999.
57. **Miles BJ:** NCI Seventh SPORE Investigators Workshop: *In situ* HSV-tk + GCV gene therapy for prostate cancer. Rockville, MD, July 12, 1999.
58. **Miles BJ:** 7th Innovations in Urologic Practice: What to do when radiation therapy fails: gene therapy. Scott Department of Urology, Baylor College of Medicine, Santa Fe, NM, September 23-24, 1999.
59. **Miles BJ:** SPIE (The International Society for Optical Engineering): High intensity focused ultrasound in the treatment of localized prostate cancer. San Jose, CA, January 22, 2000.
60. Teh BS, Shalev M, Aguilar E, **Miles BJ**, *et al*: Salvage radioactive gold seeds vs. suicide gene therapy for locally recurrent adenocarcinoma of the prostate after radiotherapy failure. *Int J Rad Oncol Biol Phys*, 46(3):785, 2000.
61. Teh BS, Woo SY, Aguilar E, **Miles BJ**, *et al*.: Combined radiotherapy and gene therapy with or without hormonal therapy in the treatment of prostate cancer – Initial experience with acute toxicity. *Int J Rad Oncol Biol Phys*, 46(3):786, 2000.
62. Schatte E, Kerns K, **Miles BJ:** Salvage radical prostatectomy: An institutional review. 79th Annual Meeting, American Urological Association, South Central Section, Montreal, Quebec, Canada, September 2000.

63. **Miles BJ**: Radiation failure: Gene therapy, RITA, HIFU. 8th Innovations in Urologic Practice, Santa Fe, NM, October 5–7, 2000.
64. **Miles, BJ**: Management of complications of pelvic irradiation. 10th Innovations in Urologic Practice, Santa Fe, NM, September 26–28, 2002.
65. Canto EI, Singh H, Shariat SF, Kattan MW, Anwuri V, Wheeler TM, Kadmon D, **Miles BJ**, Slawin KM: Systematic 12-core findings predict side-specific posterolateral extracapsular extension at RRP. Presented at the 3rd Annual Meeting on Urologic Oncology of the Society of Urologic Oncology and the NCI, Bethesda, MD, December 2002.
66. Singh H, Canto E, Shariat SF, Wheeler T, Kadmon D, **Miles BJ**, Slawin KM: Comparison of systematic sextant versus 12 core prostate biopsy in predicting pathological parameters after prostatectomy. Presented at the 3rd Annual Meeting on Urologic Oncology of the Society of Urologic Oncology and the NCI, Bethesda, MD, December 2002.
67. Teh BS, Amato RJ, Fujita T, Timme TL, **Miles BJ**, Ayala G, Wheeler TM, Kadmon D, Butler EB, Thompson TC: Combination adenoviral vector-mediated interleukin 12 gene therapy plus radiotherapy for prostate cancer #182. Presented at the 12th SPORE Investigators' Workshop, Baltimore, MD, July 10-13, 2004.
68. Stephenson AJ, Singh H, Canto E, Shariat SF, Kattan MW, Scardino PT, Kadmon D, **Miles BJ**, Wheeler TM, Slawin KM: Predictors of prostate cancer detection with an extended biopsy region in patients with a total PSA between 2.5 and 4.0 ng/mL. Presented at the 2004 American Urological Association Annual Meeting. *J Urol* 171(4 Suppl):170, abstract 639, 2004.
69. Canto EI, Singh H, Shariat SF, Nguyen C, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Stephenson AJ, Wheeler TM, Kadmon D, **Miles BJ**, Slawin KM: Comparison of %fPSA, %BPSA, [-2]pPSA/fPSA, and [-2]pPSA/BPSA for prostate cancer detection in men with total PSA concentrations between 4–10 ng/mL. Presented at the 2004 American Urological Association Annual Meeting. *J Urol* 171(4 Suppl):439, abstract 1661, 2004.
70. Canto, EI, Siingh H, Shariat SF, Nguyen C, Lamb DJ, Beck J, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Wheeler TJ, Kadmon D, **Miles BJ** and Slawin KM: Serum BPSA is a better predictor of prostate enlargement than either total PSA or free PSA in men without prostate cancer. Presented at the 2004 American Urological Association Annual Meeting. *J Urol* 171(4 Suppl):439, abstract 1532, 2004.
71. Naveen K, **Miles BJ**, Thomas W, Slawin KM: Predictors of surgical margin status: Comparison of robotic laparoscopic prostatectomy to open radical prostatectomy. Presented at the 83rd South Central Section of the American Urological Association Annual Meeting. Dublin, Ireland, September 8-12, 2004.
72. Mistry S, Mayer W, Ayala G, **Miles BJ**: Age is an independent risk factor for the presence of clinically significant prostate cancer in men over the age of 75. Presented at the InterProstate SPORE Meeting, Houston, TX, January 30 – February 1, 2005.
73. Au JL, Badalament RA, Wientjes MG, Young DC, Shen T, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, **Miles BJ**: Optimized intravesical mitomycin C treatment for superficial bladder cancer: Long-term follow-up. Presented at the 2006 American Urological Association Annual Meeting. *J Urol* 171 (4 Suppl), abstract 832, May 2006.

74. Au JL-S, Shen Z, Shen T, Badalament RA, Young DC, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, **Miles BJ**, Wientjes MG: Application of computation in translational research: Design and results of a randomized trial of intravesical mitomycin C for superficial bladder cancer. AACR 2007.
75. Gonzalez-Berjon JM, Shen S, Gardner JM, Zhai Q, **Miles B**, Ayala AG, Ro JY: A comparative histopathologic study between conventional radical prostatectomy (CRP) and robotic-assisted laparoscopic radical prostatectomy (RARP): A series of 1043 cases. Poster presentation. To be presented at the USCAP (United States and Canadian) Association of Pathology, Denver, CO, March 2008.
76. Goh A, **Miles BJ**, et al: GEARS: An assessment tool to measure robotic surgical skills. Presented at the American College of Surgeons Meeting, March 2009.
77. Goh A, **Miles BJ**, et al: Fundamentals of Robotic Surgery (FRS): Inanimate tasks for robotic surgical skills assessment and training. Presented at the American College of Surgeons Meeting, March 2009.
78. **Miles BJ**, et al: Prostate Cancer and BPH: Panelist at the 18th Annual Innovations in Urologic Practice, Houston, TX, October 15& 16, 2010.
79. Freund C, **Miles BJ**: Robotic-assisted prostatectomy is a safe treatment option for patients age 75 and above. Presented at the 2010 American College of Surgeons Annual Meeting.
80. Ayala G, **Miles BJ**: Predicting prostate cancer specific death – is it in the cancer? Presented at the 2010 American College of Surgeons Annual Meeting.
81. Goh A, Aghazadeh M, Krasnow, Stewart J, **Miles B**. Technique for Robotic Intracorporeal Continent Cutaneous Urinary Diversion. Presented at the 109th Annual Meeting of the American Urological Association, Orlando, FL. Sunday, May 18, 2014.
82. Bianco F, Albala D, Belkoff L, Cynwyd B, **Miles B**, Peabody J, He W, Bradt J, Haas G, Ahlering T. Late-Breaking Abstract: Urinary Continence after Robotic Prostatectomy: Results from a randomized, double-blind multi-center phase 4 Clinical Trial evaluating Solifenacin Succinate versus Placebo. Presented at the 109th Annual Meeting of the American Urological Association, Orlando, FL Sunday, May 18, 2014.
83. Aghazadeh M, Mercado M, Pan M, Srikishen N, **Miles B**, Link R, Dunkin B, Goh A. Proficiency-based robotic training curriculum yields improvements in robotic clinical performance: A randomized controlled study. Abstract: PD19-08. Presented at the 110th Annual Meeting of the American Urological Association, New Orleans, LA. Saturday, May 16, 2015.
84. Srikishen N, Abreu A, Aghazadeh M, Pan M, Miranda G, Aron M, **Miles B**, Gill I, Desai M, Goh A. Robotic salvage cystectomy is safe: multi-institutional perioperative outcomes. Abstract: PD31-04. Presented at the 110th Annual Meeting of the American Urological Association, New Orleans, LA. Sunday, May 17, 2015.
85. Srikishen N, Pan M, Aghazadeh M, **Miles B**, Goh A. Robotic salvage cystectomy: Tips and tricks Abstract: V8-14. Presented at the 110th Annual Meeting of the American Urological Association, New Orleans, LA. Sunday, May 17, 2015.

86. Dias N, Peng Y, **Miles B**, Khavari R, MacDonnell V, Boone T, Zhang Y. Urethral Mobility Study with a Computational Model of the Male Pelvis. PD49-07. Presented at the 111th Annual Meeting of the American Urological Association, San Diego, CA. Tuesday, May 10, 2016.

FILMS, DOCUMENTARIES, AND POSTER PRESENTATIONS:

1. MacIntyre R, Peron S, **Miles BJ**, Cerny JC: Ultrasonic guided needle biopsy of prostate. Annual Meeting of the American Urological Association, New York, NY, 1986.
2. **Miles BJ**, MacIntyre R: Adenocarcinoma of the prostate [A Patient Education Film], contracted by TAP Pharmaceuticals, 1986.
3. **Miles BJ**, Lutz M, Babu VR, Cerny JC: Cytogenetic analysis of transitional cell carcinoma of the bladder. Annual Meeting of the American Urological Association, Anaheim, CA, May 1987.
4. Golden J, Michael F, **Miles BJ**, Petrozzi C: Disseminated intravascular coagulation [DIC] in metastatic prostate carcinoma – Resolution following treatment with leuprolide, A synthetic gonadotropin releasing hormone agonist. ACP Meeting, Lansing, MI, May 1987.
5. Peron S, **Miles BJ**, Farah RN: Trans-perineal ultrasonic guided needle aspiration of the seminal vesicles. Annual Meeting of the American Urological Association, Anaheim, CA, May 1987.
6. **Miles BJ**, Melser M: The urologic manifestations of AIDS. Annual Meeting of the American Urological Association, Boston, MA, 1988.
7. Babu VR, **Miles BJ**, Cerny JC, Crissman JD, Weiss L, Van Dyke DL: A prospective study of 92 bladder cancer patients: Cytogenetics, Histopathology and Tumor Behavior. American Society of Human Genetics, June 1988.
8. **Miles BJ**, Crissman JD, Liu BS, Zarbo RJ, Johnson TL, Babu VR: Diagnosis of urothelial neoplasia. 13th International Meeting of the Society for Analytical Cytology, Breckenridge, CO, September 1988.
9. Liu BC, Zarbo RJ, Crissman JD, **Miles BJ**, Cerny JC: Detection of urothelial neoplastic cells using monoclonal E-7. 13th International Meeting of the Society for Analytical Cytology, Breckenridge, CO, September 1988.
10. **Miles BJ**, Schervish EW, *et al*: Flow cytometry and cytology in transitional cell carcinoma of the bladder. Annual Meeting of the American Urological Association, North Central Section, Orlando, FL, November 1988.
11. **Miles BJ**, Cerny JC, Crissman JD, Babu VR: DNA content and cytogenetic analysis of urothelial neoplasia. Annual Meeting of the American Urological Association, North Central Section, Orlando, FL, September 1988.
12. Peters JM, Cerny JC, Abrash MP, Crissman J, **Miles BJ**: Prognostic significance of nuclear DNA content in prostate cancer. Annual Meeting of the American Urological Association, North Central Section, Orlando, FL, 1988.
13. Peters JM, Cerny JC, Abrash MP, Crissman J, **Miles BJ**: Prognostic significance of nuclear DNA content in prostate cancer. Annual Meeting of the Canadian Urologic Association, Quebec City, Canada, September 1989.

14. Peters JM, **Miles BJ**, Crissman JD, Cerny JC: Prognostic significance of nuclear DNA content in localized prostatic adenocarcinoma using image analysis. Annual Meeting of the American Urological Association, New Orleans, LA, May 1990.
15. Peters JM, **Miles BJ**, Cerny JC, Crissman JD: Prostatic significance of DNA content in prostate carcinoma, UICC 15th International Cancer Congress, Hamburg, West Germany, August 16-22, 1990.
16. **Miles BJ**, Beck RJ, Kattan M, Scardino PT: Profiles in management – Audio Tape, Computer modeling and prostate cancer. Profile #2, February 1995.
17. **Miles BJ**, Wheeler T, Scardino PT: Current staging of prostate cancer – Movie. BARD Urologic, January 1996.
18. Cowen M, Kattan, M, Cahill D, **Miles BJ**: The value or utility of prostate cancer states. Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.
19. **Miles BJ**: Prostate cancer – Detection. Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.
20. **Miles BJ**: Getting the jump on prostate cancer – Movie. St. Luke's Episcopal Hospital and ZENECA Pharmaceuticals, November 1996.
21. **Miles BJ**: Profiles in Decision – Outcomes Research in Quality of Life Assessment. Audiotape. American Urological Association, August 13, 1997.
22. **Miles BJ**: Outcomes, Practice Patterns. Annual Meeting of the American Urological Association, San Diego, CA, May 30 – June 4, 1998.
23. Sadeghi F, **Miles BJ**: Successful treatment of post-radiation rectourinary fistulae with an aggressive, multidisciplinary surgical approach. 4th Annual SUO Meeting, Bethesda, MD, December 5-6, 2003.
24. Pastuszak, AW, **Miles BJ**, Lipshultz LI, Khera M: Testosterone Replacement Therapy in Patients with High Risk Prostate Cancer After Radical Prostatectomy: Long-Term Follow-Up. Société Internationale d'Urologie Annual Meeting, Fukuoka, Japan, September 29 – October 4, 2012.
25. Ayala G, Freund, C, Miles BJ, Au J, Ittmann M, Rowley D: Influence of the Neural Microenvironment in Prostate Cancer. Société Internationale d'Urologie Annual Meeting, Fukuoka, Japan, September 29 – October 4, 2012.

PRESENTATIONS:

1. Neurological manifestations of adenocarcinoma of the prostate. Kimbrough Urologic Seminar, Denver, CO, 1981.
2. Fernandez JA, **Miles BJ**, Buck AS, Gibbons RP: Renal carbuncle – Comparison between surgical open drainage and closed percutaneous drainage. Northwest Sectional Meeting, Vancouver, Canada, 1982.

3. Treatment of non-infectious hemorrhagic cystitis. Kimbrough Urologic Seminar, San Francisco, CA, Northwest Sectional Meeting, Portland, OR, 1983.
4. A new method for controlling bleeding in radical prostate surgery. Kimbrough Urologic Seminar, San Francisco, CA, 1983.
5. Renal calculi in blacks. Kimbrough Urologic Seminar, Scottsdale, AZ, 1984.
6. Bladder infections including recurrent cystitis. AUA Postgraduate Course, Dearborn, MI, March 1985.
7. Radical prostatectomy vs. interstitial I-125 radiation for adenocarcinoma of the prostate. Annual Meeting of the American Urological Association, Atlanta, GA, 1985.
8. Cytogenetics of transitional cell carcinoma. Southwest Oncology Group, Detroit, MI, September 1985.
9. Cytogenetics of transitional cell carcinoma. Kimbrough Urological Seminar, Seattle, WA, 1985.
10. Nonrandom chromosome changes in transitional cell carcinoma of the bladder. Somatic Cell Genetics Conference, Key West, FL, January 1986.
11. Impotence evaluation and treatment. Henry Ford Fairlane Medical Staff Meeting, Detroit, MI, February 1986.
12. Treatment of advanced prostate cancer. Grand Rounds, Oakwood Hospital, Dearborn, MI, May 13, 1986.
13. Diagnosis and treatment of superficial transitional carcinoma of the bladder with hematoporphyrin derivative and laser photodynamic treatment. 34th Annual Kimbrough Urological Seminar, San Antonio, TX, October 1986.
14. Advanced prostate cancer. Heritage Hospital, Houston, TX, October 1986.
15. Diagnosis and treatment of superficial transitional carcinoma of the bladder with hematoporphyrin derivative and laser photodynamic therapy. 34th Annual Kimbrough Urological Seminar, San Antonio, TX, October 1986.
16. Ultrasound guided needle biopsy of the prostate gland. American Urological Association, North Central Section, Palm Springs, CA, November 1986.
17. Implants in the management of localized prostatic carcinoma. American Urological Association, North Central Section, Detroit, MI, September 1987.
18. Review of prostatic ultrasound as a diagnostic modality: The Henry Ford Hospital experience. American Urological Association, North Central Section, Detroit, MI, September 1987.
19. Urologic manifestation of AIDS. American Urological Association, North Central Section, Detroit, MI, September 1987.
20. Urologic complications of AIDS. 35th Annual Kimbrough Urological Seminar, Washington, DC, November 1987.

21. Benign testicular tumors: Is pre-orchietomy diagnosis possible? 35th Annual Kimbrough Urological Seminar, Washington, DC, November 1987.
22. Diagnosis of urothelial neoplasia. 13th International Meeting of the Society for Analytical Cytology, Breckenridge, Colorado, September 4-9, 1988.
23. A prospective study of 92 bladder cancer patients: Cytogenetics, Histopathology and Tumor Behavior. American Society of Human Genetics, June 10, 1988.
24. Diagnosis of urothelial neoplasia. Society for Analytical Cytology, Breckenridge, CO, September 4-9, 1988.
25. Detection of urothelial neoplastic cells using monoclonal E-7. Breckenridge, CO, September 4-9, 1988.
26. Risk factors for perineal/prostate cancer after needle biopsy. American Urological Association, Mid Atlantic Section, Baltimore, MD, November 1988.
27. **Miles BJ**, Poffenberger R: Primary squamous cell carcinoma of the bladder. Kimbrough Urologic Meeting, San Antonio, TX, December 4, 1989.
28. **Miles BJ**, Peabody J, Zarbo R, Johnson T, Crissman JD: Diagnosis of urothelial neoplasia comparing FCM and cytology. American Urological Association, North Central Section, Chicago, IL, September 1989.
29. Sirls LT, **Miles BJ**, Babu VR: Chromosomal changes in transitional cell carcinoma of the bladder. Annual Meeting of the American Urological Association, Toronto, Ontario, Canada, 1991.
30. **Miles BJ**: Is nerve-sparing cancer sparing in adenocarcinoma of the prostate. Annual Meeting of the American Urological Association, North Central Section, Palm Springs, CA, October 1990.
31. **Miles BJ**, Reanalysis of the PORT model for management of localized prostate cancer. Schering Corporation Speakers Update Symposium, Naples, FL, February 1994.
32. Markov Fleming, **BJ Miles**: Prostate cancer management. The Texas Association of Genitourinary Surgeons Spring Meeting, Houston, TX, April 10, 1994.
33. Watchful waiting – Patient selection and outcomes analysis. Baylor College of Medicine, 3rd Innovations in Urologic Practice, Houston, TX, February 1996.
34. 3rd Innovations in Urologic Practice: Intermittent androgen ablation. Scott Department of Urology, Baylor College of Medicine. Houston, TX, February 1996.
35. 3rd Innovations in Urologic Practice: Novel strategies for intravesical chemotherapy and immunotherapy. Scott Department of Urology, Baylor College of Medicine. Houston, TX, February 1996.
36. 3rd Innovations in Urologic Practice: Surgical management for BPH. Scott Department of Urology, Baylor College of Medicine. Houston, TX, February 1996.
37. Prostate cancer outcomes research project update, AUA Board of Directors, Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.

38. 4th Innovations in Urologic Practice: Neoadjuvant androgen ablation. Scott Department of Urology, Baylor College of Medicine. Houston, TX, January 1997.
39. 4th Innovations in Urologic Practice: Cost analysis of prostate cancer management. Scott Department of Urology, Baylor College of Medicine. Houston, TX, January 1997.
40. PSA vs. digital rectal exam. 14th Annual Cancer Conference on Current Tools in the Prevention and Detection of Cancer, Columbia Spring Branch Medical Center, Houston, TX, June 18, 1997.
41. Inaugural National Meeting of the Genito-Urinary Oncology Group, Sydney, New South Wales, July 25-27, 1997.
 - a. The Baylor experience with radical prostatectomy
 - b. A cost analysis of prostate cancer management in the USA
 - c. The Baylor Department of Urology prostate cancer gene therapy experience
42. 5th Innovations in Urologic Practice, Scott Department of Urology, Baylor College of Medicine, Santa Fe, NM, September 25-27, 1997.
 - a. Neo-adjuvant and adjuvant therapy for locally advanced disease
 - b. New horizons in the management of metastatic prostate cancer
43. 6th Innovations in Urologic Practice, Scott Department of Urology, Santa Fe, NM, September 24, 1998.
 - a. The changing role of hormonal therapy for managing prostate cancer patients
 - b. Gene therapy for prostate cancer: What have we learned and where are we headed
44. Cancer Care – Quality of Life and Outcomes Symposium: The Value or Utility of Prostate Cancer States. Chicago, IL, November 14, 1998.
45. Faculty: 7th Annual Genitourinary Conference. Status of Baylor Clinical Gene Therapy Trial. Scott Department of Urology, Baylor College of Medicine. Houston, TX, February 18-19, 1999.
46. Course Instructor: 94th Annual Meeting of the American Urological Association. The Treatment of Metastatic Prostate Cancer, Dallas, TX, April 30 – May 6, 1999,
47. The Economics of Prostate Cancer. World Health Organization 2nd International Consultation on Prostate Cancer. Paris, France, June 28, 1999.
48. NCI Seventh SPORE Investigators Workshop: *In Situ* HSV-tk + GCV Gene Therapy for Prostate Cancer. Rockville, MD, July 12, 1999.
49. 7th Innovations in Urologic Practice: What To Do When Radiation Therapy Fails: Gene Therapy. Scott Department of Urology, Baylor College of Medicine, Santa Fe, NM, September 23-24, 1999.
50. SPIE (The International Society for Optical Engineering): High Intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer. San Jose, CA, January 22, 2000.
51. 8th Innovations in Urologic Practice: Radiation Failure: Gene Therapy, RITA and HIFU. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, October 5-7, 2000.

52. 9th Innovations in Urologic Practice: Radiation Prostatectomy vs. XRT for Clinically Localized Prostate Cancer. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, October 4-6, 2001.
53. 9th Innovations in Urologic Practice: Laparoscopic Radical Nephrectomy. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, October 4-6, 2001.
54. 11th Innovations in Urologic Practice: Cryotherapy for Prostate Cancer. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, September 18-20, 2003.
55. 12th Innovations in Urologic Practice: Minimally Invasive Therapy for BPH: TUNA, TUMT and the MIST Trial. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, September 30 – October 2, 2004.
56. 12th Innovations in Urologic Practice: Cryosurgery – The Baylor Experience. Scott Department of Urology, Baylor College of Medicine. Santa Fe, NM, September 30 – October 2, 2004.
57. 2005 Texas Academy of Internal Medicine, The Texas Chapter of the ACP annual Scientific Meeting. PSA and Beyond: The Present and Future of Prostate Cancer Testing. The Woodlands, TX, November 5, 2005.
58. Genitourinary Oncology Program Seminar Series: Radical Prostatectomy: Tailoring the Operation. The Methodist Hospital, Houston, TX, June 19, 2007.
59. 17th Innovations in Urologic Practice: Salvage Radiation Therapy. Scott Department of Urology, Baylor College of Medicine. Houston, TX, October 2-3, 2009.
60. International Robotic Urology Symposium: Penile Preservation Post Radical Prostatectomy. Las Vegas, NE, January 16, 2010.
61. Methodist International Lectures Series 2010: Surgical Skills & Robotics: Robotic Surgery in Urologic Cancers. Houston, TX, February 2, 2010.
62. Sexual Medicine Society Meeting: Penile Preservation Post Radical Prostatectomy. San Francisco, CA, May 30, 2010.
63. New Innovations in General Surgery and Robotics Symposium: Training Curriculums in Robotic Surgery. Houston, TX, November 3-5, 2011.
64. 2012 Texas Urological Society Annual Meeting: Prostate Cancer: New Agents. Houston, TX, June 8, 2012.
65. 19th Innovations in Urologic Practice: A New Screening Era in Prostate Cancer? Santa Fe, NM, October 5-7, 2012.
66. 19th Innovations in Urologic Practice: The Role of the Urologist in New Treatments for Advanced Prostate Cancer. Santa Fe, NM, October 5-7, 2012.
67. Methodist International Lecture Series 2012: Prostate Cancer and Robotic Surgery In Urology. Houston, TX, October 16, 2012.
68. 20th Innovations in Urologic Practice. Importance of Perineural Invasion in Prostate Cancer. Santa Fe, New Mexico. September 28, 2013.

VISITING PROFESSORSHIP/GUEST LECTURER:

1. Walter Reed Army Medical Center, Washington, DC, November 2-4, 1987.
2. Honolulu Urologic Society, Honolulu, Hawaii, May 2-4, 1988.
3. Walter Reed Army Medical Center, Washington, DC, September 8-9, 1988.
4. Henry Ford Hospital, Symposium on Adenocarcinoma of the Prostate, Detroit, MI, June 17, 1988.
5. Advances in the treatment of urologic malignancies [University of Colorado], Dana Point, CA April 6-9, 1989.
6. Round table on metastatic prostate cancer [Excerpta Medica], Dallas, TX, August 28-29, 1989.
7. Advances in urology? Urologic Oncology, Annual Meeting of the Michigan State Medical Society, November 8, 1989.
8. Ohio State University, December 8-9, 1989.
9. Ohio State Urologic Outing, Salt Fork, OH, June 14-15, 1990.
10. Good Samaritan Hospital, USC Teaching Hospital, June 19, 1990.
11. Management of recurrent transitional cell carcinoma of the bladder [Schering Corporation], Newark, NJ, June 20, 1990.
12. Prostate cancer: An update. University of California, San Diego, CA, September 14-16, 1990.
13. Chromosomal changes in transitional cell carcinoma of the bladder. Baylor College of Medicine, Scott Department of Urology, Houston, TX, March 1993.
14. The impact of treatment of prostate cancer. International Symposium on the Epidemiology of Prostate Disease, Royal College of Surgeons, Edinburgh, Scotland, April 22-23, 1994.
15. The case for radical prostatectomy in localized carcinoma of the prostate. Kaiser Permanente Urology Symposium, Lake Arrowhead, CA, June 16, 1994.
16. The dilemma of prostate cancer. Phoenix Urological Society, Phoenix, AZ, June 20, 1994.
17. Newest developments in the management of prostate cancer. Thomas W. Green Memorial Lecture, East Tennessee State University, Quillen College of Medicine, Bristol, TN, October 7, 1994.
18. Urology in the 90s: Watchful waiting: To treat or not to treat? Discovery International Symposium, Orlando, FL, October 20-22, 1994.
19. Outcomes analysis and prostate cancer. Visiting Professor, Wayne State University, Detroit, MI, December 15-16, 1994.

20. Bladder cancer: State of the Art Therapy Symposium. New treatment strategies for clinical stage Ta, T1, T1a. Houston, TX, February 28, 1995.
21. Controversies in the management of prostate cancer. Charlotte County Medical Society, Port Charlotte, FL, March 20, 1995.
22. Surgical techniques with the vaporization electrode. Urology Symposium. Physiology of electrovaporization of the prostate, Baylor College of Medicine Houston, TX, April 1, 1995.
23. Early detection and treatment of prostate cancer: Prostate cancer – Treatment vs. watchful waiting. Postgraduate Course, Annual Meeting of the American Urological Association, Las Vegas, NV, April 26, 1995.
24. Outcomes analysis for prostate cancer. Henry Ford Hospital Annual Urology Symposium, Dearborn, MI, August 1995.
25. Post radiation salvage prostatectomy. Humboldt Medical School, Department of Urology, Berlin, Germany, November 10-11, 1995.
26. Does a positive RT-PCR PSA assay mean micrometastases? Humboldt Medical School, Department of Urology, Berlin, Germany, November 10-11, 1995.
27. Treatment options for stage T3 prostate cancer. Humboldt Medical School, Department of Urology, Berlin, Germany, November 10–11, 1995.
28. Salvage prostatectomy cancer and leukemia Group B. Fall Meeting, Dallas, TX, November 3, 1995.
29. Treatment of prostate cancer. Fourth Annual Society of Urologic Nurses Seminar, December 1995.
30. Current diagnosis and management of bladder cancer. Good Samaritan Hospital Grand Rounds, Corvallis, OR, February 16, 1996.
31. Screenings for Baylor College of Medicine 20th Annual Review Course in Family Medicine, Houston, TX, April 23, 1996.
32. Public attitudes and concerns about prostate cancer: An AUA/Gallup survey. Plenary Session, Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.
33. What's new in the treatment of advanced prostate cancer? AUA Postgraduate Course, Orlando, FL, May 5, 1996.
34. Highlights – Prostate cancer. Plenary Session, Annual Meeting of the American Urological Association, Orlando, FL, May 4-9, 1996.
35. Prostate cancer – Screening, evaluation, and treatment. Essentials of prostate and genitourinary imaging. The Foundation for Health Education. San Antonio, TX, October 11-12, 1996.
36. Trends in the diagnosis, treatment options and management of prostate cancer. Visiting Professor, University of Maryland, Baltimore, MD, February 13, 1997.
37. Outcomes analysis/quality of life in prostate cancer. Visiting Professor, State University of New York, Syracuse, NY, March 13, 1997.

38. Gene therapy for radiorecurrent prostate cancer. Visiting Professor, State University of New York, Syracuse, NY, March 13, 1997.
39. Prostate cancer: Adjuvant, neoadjuvant therapy. AUA Postgraduate Course, New Orleans, LA, May 20, 1997.
40. Trends in the management of prostate cancer. Visiting Professor, National Visiting Professor Academy, sponsored by educational grant from Hoechst Marion Roussel, Hyatt Regency Grand Cayman, June 10-13, 1997.
41. Cancer of the prostate: Diagnosis and treatment of benign prostatic hyperplasia. XII Jornada Cientifica Del Centro Medico Paitilla, Panama City, Panama, June 18-19, 1997.
42. The Baylor experience with prostate cancer. First Annual Meeting of the Australian Genito-Urinary Oncology Group. New South Wales, Australia, July 25-27, 1997.
43. Prostate cancer screening - To screen or not to screen. Visiting Professor, Riverside Methodist Hospital, Columbus, OH, September 9, 1997.
44. Cost analysis of prostate cancer/Gene therapy in prostate cancer. Visiting Professor, Long Island Jewish Medical Center, New Hyde Park, NY, October 16-17, 1997.
45. An update on the diagnosis, treatment options and management of prostate cancer. Visiting Professor, Urology Associates, P.C., Nashville, TN, October 23, 1997.
46. The treatment of localized prostate cancer. Congress of the Brazilian Society of Urology, Hoechst Marion Roussel Symposium, Blumenau (St. Catarina), Brazil, November 9, 1997.
47. Visiting Professor, The Puerto Rico Urological Society Annual Meeting, San Juan, Puerto Rico, November 15-16, 1997.
 - a. An update: Diagnosis, treatment and management of prostate cancer
 - b. The future of urology in the next millennium
48. Neoadjuvant and adjuvant therapy for locally advanced prostate cancer. 5th Annual Innovations in Urologic Practice (Baylor College of Medicine), Santa Fe, NM, September 25-27, 1997.
49. Adjuvant, neoadjuvant therapy in prostate cancer. AUA Postgraduate Course, San Diego, CA, June 2, 1998.
50. The economics of prostate cancer. Wayne State University Annual Symposium, Traverse City, MI, August 12, 1999.
51. The management of prostate cancer. Xalapa Medical Center, Xalapa, Mexico, October 21, 2000.
52. Control of primary tumor. 2nd Annual Southwest Kidney Cancer Conference, Houston, TX, September 25, 2004.
53. The current and future management of adenocarcinoma of the prostate. 26th National Medical Convention, Houston, TX, October 8-11, 2004.
54. Current management of advanced prostate cancer. AUA Postgraduate Course, Dallas, TX, June 5, 2005.

55. Faculty Member, Benign Prostatic Hyperplasia, AUA Annual Review Course, Dallas, TX, June 9-12, 2005.
 - a. Anatomy, physiology and pharmacology of the prostate
 - b. Pathophysiology of BPH; evaluation of the patient with symptoms of BPH
 - c. Conservative management of BPH (watchful waiting and medical management)
 - d. BPH guidelines
 - e. Surgical and other nonmedical management of BPH (including TURP, TUIP, open prostatectomy, laser thermotherapy, stent, TUNA, focused ultrasound and others)
56. Visiting Professor, Future Treatment of Prostate Cancer. Symposium on Prostate Cancer, FAQs and Current Issues in the Medical Management of Prostate Cancer. Philippine Urological Association (PUA, Inc.), Quezon City, Philippines, August 3, 2005.
57. Visiting Professor, Northwestern Ohio Urological Association, Medical University of Ohio, Toledo, OH, August 25-26, 2005.
 - a. Prostate cancer screening: Ethical dilemmas
 - b. Case studies of patients
58. Invited Lecturer, Gene Vaccine Therapy. Grand Rounds, Makati Medical Center Hospital, Manila, Phillipines, January 29 – February 5, 2006.
59. Invited Speaker, International Society for Brachial Plexus and Peripheral Nerve Injury Inaugural Conference. “Radical Retropubic Prostatectomy: Tailoring the Operation, the Role of Nerve Graft.” Houston, TX, March 25, 2006.
60. Invited Speaker, Surgical Procedures, Prostate and Kidney Cancer Symposium, The Methodist Hospital, Houston, TX, April 29, 2006.
61. Faculty Member, Benign Prostatic Hyperplasia, AUA Annual Review Course, Dallas, TX, July 20-23, 2006.
 - a. Anatomy, physiology and pharmacology of the prostate
 - b. Pathophysiology of BPH; evaluation of the patient with symptoms of BPH
 - c. Conservative management of BPH (watchful waiting and medical management)
 - d. BPH guidelines
 - e. Surgical and other non-medical management of BPH (including TURP, TUIP, open prostatectomy, laser thermotherapy, stent, TUNA, focused ultrasound and others)
62. Invited Speaker, The 10th Annual Optimal Management of the Adult Medicine Patient. “Prostate Cancer.” Held at Trevisio’s, Houston, TX, September 28-30, 2006.
63. Visiting Professor and Surgeon, Xinjiang Medical University. “Prostate Cancer – What’s New.” Xi'an, China, November 11-13, 2006.
64. Visiting Professor, Xinjiang Medical University. “Robotic Prostatectomy.” Xi'an, China, April 1-7, 2007.
65. Invited Speaker, 2007 Patient and Caregiver Kidney and Prostate Cancer Symposium. “The Role of Robotic Surgery.” The Methodist Hospital, Houston, TX, April 28, 2007.

66. Invited Speaker, XXXVI Seminarios Científicos I Congreso Científico Internacional. “A la Vanguardia en los Nuevos Retos de la Atención Hospitalaria.” Hospital Santo Tomás, Panama, September 20, 2007.
 - a. Management of renal masses
 - b. Diagnosis and management of prostate cancer
67. Invited Speaker, The 11th Annual Optimal Management of the Adult Medicine Patient. “Prostate Cancer for the Primary Care Doctor.” Baylor College of Medicine, Department of Medicine, and Ben Taub General Hospital, Houston, TX, September 27, 2007.
68. Invited Speaker, Texas State Assembly. “Robotic Prostatectomy”. Houston 2008 Workshop, Houston, TX, August 9 & 10, 2008.
69. Invited Speaker, Methodist Surgical Nursing Conference. “Robotic Surgery in Urologic Cancers”. The Methodist Hospital, Houston, TX, October 12, 2009.
70. Invited Speaker, Grand Rounds. “Stromagenic Cancer of the Prostate”. Baylor College of Medicine, Scott Department of Urology, Houston, TX, November 4, 2009.
71. Invited Speaker, River Oaks Men’s Breakfast Club. “Prostate Cancer: The Controversy”. Houston, TX, June 9, 2010.

PAST PROJECTS:

1. Developing a national “Patterns of Care/Outcomes Analysis Center” for the American Urological Association.
2. Clinical Principal Investigator in a large V.A. study of “quality outcomes” in the treatment of prostatic diseases.
3. Markov modeling in medical decision making as applied to urologic disorders.
4. Apoptotic bodies in prostate carcinoma as prediction for response to treatment/progression.
5. National Clinical Director, Veterans Administration’s efforts to achieve quality health care delivery through identification and implementation of “best practices.”
6. Director, Scott Department of Urology “Prostate Cancer Research Initiative,” an effort to create an in-house funding source in excess of \$5,000,000 to support prostate cancer research.
7. Clinical Director, Scott Department of Urology, Baylor College of Medicine, Prostate Cancer Gene Therapy Programs.
8. Director, Prostate Cancer Gene Therapy Clinical Research (6 projects ongoing).

ADMINISTRATIVE ACTIVITIES:

- Physician Administrator, Scott Department of Urology Education Task Force, Baylor College of Medicine, Houston, TX. In charge of budgeting, staffing and overseeing of student, resident and fellowship programs, 1994.

- Budget Director, Clinical Research Unit, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1994.
- Chief, Urology Service, St. Luke's Episcopal Hospital, Houston, TX, 1994-Present.
- Chairman, Managed Care Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1995.
- Member, Managed Care Committee, Baylor College of Medicine, Houston, TX.
- Chairman, Urologic Network Development Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- BaylorMedCare External Relations Committee, Baylor College of Medicine, Houston, TX.
- Developed weekly Prostate Screening Center at St. Luke's Episcopal Hospital, Houston, TX.
- Attended the Harvard "Program for Chiefs of Clinical Services," February 5-17, 1995.
- Attended the Medical Leadership Council Meeting on "Negotiating Managed Care Contracts" as a representative of St. Luke's Episcopal Hospital, Houston, TX, March 1996.
- Medical Director, Baylor Urologic Network (A Houston metropolitan network of 40 urologists dedicated to providing high-quality care for managed care organization third-party payors), September 1996-2000.
- Interim Chief, Urology Service, The Methodist Hospital, Houston, TX, May 1998-2000.
- Member, Graduate Medical Education Committee, Baylor College of Medicine, Houston, TX, 1998-1999.
- President, Houston Urologic Society, 1999-2004.
- Medical Director, TX Cancer Institute, St. Luke's Episcopal Hospital. Mission: To develop and initiate the programmatic creation of a new cancer center in the Texas Medical Center.
- Member, Executive Committee, Baylor Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 2004.
- Member, Executive Committee, Center for Integrative Medicine, Baylor College of Medicine/St. Luke's Episcopal Hospital, Houston, TX, 2004.
- Member, Baylor "Academic Model of Care" (AMOC).
- Member, Baylor College of Medicine International Activities Committee, 2006-2008.
- Member, Baylor College of Medicine Endowed Chair and Professorship Review and Appointment Committee, 2007-2008.
- Governing Body Host and Participant, Healthcare Executive Summit by Chairs & Chiefs for Chairs & Chiefs, Houston, Texas, June 20, 2012.

EDUCATION:

Current:

Past:

- Director, Resident Education, Henry Ford Hospital, Detroit, MI.
- Program Director, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- In charge of resident education for four residents rotating per quarter on the Urology Service, Veterans Affairs Medical Center, Houston, TX
- Program Director, Residency Program, Scott Department of Urology, Baylor College of Medicine, Houston, TX, 1996-2000.
- Active in SPORE Seminars, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Direct the combined Veterans Affairs/Ben Taub Urologic Conference on a biweekly basis, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Present didactic talks at the Tumor Boards, Veterans Affairs Medical Center, Houston, TX
- Responsible for urologic education for an average of two third-year medical students per month, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Leader of a weekly reading group for chief residents, preparing them for upcoming Urology Boards, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Responsible for Grand Rounds every 3 months, Scott Department of Urology, Baylor College of Medicine, Houston, TX
- Active in presenting/mentoring medical student core lectures at Baylor College of Medicine.
- Member, Residency Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Member, Fellowship Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
- Member, Medical Student Educational Committee, Scott Department of Urology, Baylor College of Medicine, Houston, TX
- Mentor and resource for groups of PGY2 residents.

Signature

Date